Delaware
|
26-2222607
|
|||||
---|---|---|---|---|---|---|
(State
or other jurisdiction of
incorporation or organization) |
(I.R.S. Employer
Identification Number) |
Jon R. Sabes
Chief Executive Officer 220 South Sixth Street, Suite 1200 Minneapolis, Minnesota 55402 Tel: (612) 746-1944 (Name, address, including zip code, and telephone number, including area code, of agent for service) |
Copies to
:
Paul D. Chestovich, Esq. Maslon Edelman Borman & Brand, LLP 3300 Wells Fargo Center 90 South Seventh Street Minneapolis, Minnesota 55402 Tel: (612) 672-8200 |
---|
Large
accelerated filer
o
|
Accelerated filer
o
|
|||||
Non-accelerated filer
o
|
Smaller reporting company [X]
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Title of each class of securities
to be registered |
Amount
to be registered (1) |
Proposed
maximum offering price per share |
Proposed
maximum aggregate offering price (2) |
Amount of
registration fee (3) |
||||||||||||||
Common Stock,
$0.001 par value
|
shares | $ | $ | 15,000,000 | $ | 1,932 |
(1)
|
Includes shares purchasable by the underwriters to cover over-allotments, if any. |
(2)
|
Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule 457(o) of the Securities Act of 1933. |
(3)
|
Previously paid. |
Per Share
|
Total
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Public
offering price
|
$ | $ | 15,000,000 | |||||||
Underwriting
commissions (1)
|
$ | $ | 1,050,000 | |||||||
Proceeds to
us, before expenses
|
$ | $ | 13,950,000 |
(1)
|
See “Underwriting” beginning on page 91 for disclosure regarding compensation, including reimbursement of expenses, payable by us to the underwriters. |
Page
|
||||||
---|---|---|---|---|---|---|
1 | ||||||
2 | ||||||
10 | ||||||
12 | ||||||
28 | ||||||
29 | ||||||
30 | ||||||
31 | ||||||
32 | ||||||
48 | ||||||
71 | ||||||
77 | ||||||
79 | ||||||
80 | ||||||
82 | ||||||
84 | ||||||
85 | ||||||
89 | ||||||
91 | ||||||
94 | ||||||
94 | ||||||
94 | ||||||
F-1 |
Total
portfolio face value of policy benefits
|
$ | 771,940,000 | ||||
Average face
value per policy
|
$ | 2,699,000 | ||||
Average face
value per insured life
|
$ | 3,015,000 | ||||
Average age
of insured (yrs.) *
|
82.3 | |||||
Average life
expectancy estimate (yrs.) *
|
7.02 | |||||
Total number
of policies
|
286 | |||||
Number of
unique lives
|
256 | |||||
Demographics
|
67% Males; 33% Females
|
|||||
Number of
smokers
|
3 insureds are smokers
|
|||||
Largest
policy as % of total portfolio
|
1.30 | % | ||||
Average
policy as % of total portfolio
|
0.35 | % | ||||
Average
Annual Premium as % of face value
|
3.15 | % |
•
|
purchasing life insurance policies with expected internal rates of returns in excess of our cost of capital; |
•
|
paying the premiums and costs associated with the life insurance policy until the insured’s mortality; |
•
|
obtaining a large and diverse portfolio to mitigate actuarial risk; |
•
|
maintaining diversified funding sources to reduce our overall cost of financing; |
•
|
engaging in hedging strategies that reduce potential volatility to our cost of financing; and |
•
|
maintaining rigorous portfolio monitoring and servicing. |
•
|
Industry Experience : We have actively participated in the development of the secondary market of life insurance as a principal purchaser and financier since 2006. Our position within the marketplace has allowed us to evaluate over 36,000 life insurance policies for possible purchase, thereby gaining a deep understanding of the variety of issues involved when purchasing life insurance policies in the secondary market. We have participated in the leadership of various industry associations and forums, including the Life Insurance Settlement Association (LISA) and the Insurance Studies Institute (ISI). Our experience gives us confidence in building a portfolio of life insurance policies that will perform to our expectations. |
•
|
Operational Platform : We have built an operational platform and systems for efficiently tracking, processing, and servicing life insurance policies that we believe provide competitive advantages when purchasing policies in the secondary marketplace, and servicing the policies once acquired. |
•
|
Origination and Underwriting Practices : We seek to purchase life insurance policies that meet published guidelines on what policies would be accepted in a rated securitization. We purchase only permanent life insurance policies we consider to be non-contestable and that meet stringent underwriting criteria and reviews. We consider a life insurance policy to be “non-contestable” once applicable state law prohibits the insurer from challenging the validity of the policy due to fraud. In this regard, state non-contestability laws generally require a period of one to two years to elapse after the initial issuance of the policy before that policy is considered non-contestable under state law. Non-contestability laws do not, however, prevent an insurer from challenging the validity of a policy procured by fraud for lack of an insurable interest at the time at which the policy was purchased (such as is the case with “stranger-originated” life insurance policies). |
•
|
Origination Relationships : We have established origination relationships with over 300 life insurance policy brokers and insurance agents who submit policies for our purchase or financing. Our referral base knows our underwriting standards for purchasing life insurance policies in the secondary market, which provides confidence in our bidding and closing processes and streamlines our own due-diligence process. We expect to expand our origination relationships and channels with the proceeds of this offering. |
•
|
Life Expectancy Methodology : We generally rely on two life expectancy estimates from independent third-party medical-actuarial underwriting firms to develop our own life expectancy estimate. For a majority of our life insurance policy purchases, we rely on estimates obtained from 21st Services and AVS Underwriting to develop our life expectancy estimate. We may also obtain life expectancy estimates from Fasano Associates and Examination Management Services, Inc. |
•
|
Pricing Software and Methodology : We use actuarial pricing methodologies and software tools that are built and supported by leading independent actuarial service firms such as Modeling Actuarial Pricing Systems, Inc. (“MAPS”) for calculating our expected returns. |
•
|
Diversified Funding : We have actively developed diversified sources for accessing capital markets in support of our buy-and-hold strategy for our portfolio of life insurance policies, ranging from institutional bank financing to a network of broker-dealers registered with the Financial Industry Regulatory Authority (“FINRA”), many of whom have participated in one or more of our Series I Secured note financing, our Series A preferred stock financing, or our Renewable Secured Debenture financing. If in the future we determine to offer different kinds of investment products, we expect to leverage the network of broker-dealers that we have built over time. |
•
|
Relatively New Market : The purchase and ownership of life insurance policies acquired in the secondary market is a relatively new and evolving market. Our ability to source and purchase life insurance policies at attractive discounts materially depends on the continued development of the secondary market for life insurance. This includes the solvency of the life insurance companies that pay the face value of the life insurance benefits, the accuracy of life expectancy assumptions, and other factors beyond our control. |
•
|
Assumptions About Valuation of Our Assets : The valuation of our portfolio of life insurance policies, which is the principal asset on our balance sheet, requires us to make material assumptions that may ultimately prove to be incorrect. These assumptions include appropriate discount rates, cash flow projections, and actuarial life expectancies, any of which may ultimately prove to be inaccurate. |
•
|
Ability to Expand Our Portfolio : Our business model relies on achieving actual results that are in line with the results we expect to attain from our investments in life insurance policy assets. In this regard, we believe that the larger the portfolio of life insurance policies we own, the greater likelihood we will achieve actuarial results matching our expected results. Although we plan to expand the number of life insurance policies we own using proceeds raised from the sale of our Renewable Secured Debentures and our common stock in this offering, we may be unable to meet this goal. And, even if we attain the goal, we may not achieve the actuarial results we expect. |
•
|
Reliance on Financing : To date, we have chosen to finance our business almost entirely through the issuance of debt, including the sale of Renewable Secured Debentures, Series I Secured notes, and a senior revolving credit facility. Our business model expects that we will have continued access to financing in order to purchase a large and diversified portfolio of life insurance policies, and thereafter pay the attendant premiums and servicing costs of maintaining that portfolio. In building a larger portfolio of policies, our goal is to remain diversified in terms of insurance carriers and the medical conditions of insureds. We believe that diversification among insurers and medical conditions will lower our overall risk, and that a larger number of policies will provide our portfolio with greater actuarial stability. We will be required to rely on our access to financing until such time as we experience a significant amount of mortality within our portfolio and begin receiving significant revenues from the receipt of insurance policy benefits. Nevertheless, we may not receive insurance policy benefits that match our cash flow projections. |
•
|
Risk of Investment in Life Insurance Policies : Our investments in life insurance policies have inherent risks, including fraud and legal challenges to the validity of the policies, as well as the possibility that the seller of the policy may have provided us with inaccurate or misleading information. |
•
|
Effects of Regulation : Our business is subject to complex state regulation. Changes in state laws and regulations governing our business, or changes in the interpretation of such laws and regulations, could negatively affect our business. |
•
|
are not required to obtain an attestation and report from our auditors on our management’s assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; |
•
|
are not required to provide a detailed narrative disclosure discussing our compensation principles, objectives and elements and analyzing how those elements fit with our principles and objectives (commonly referred to as “compensation discussion and analysis”); |
•
|
are not required to obtain a non-binding advisory vote from our stockholders on executive compensation or golden parachute arrangements (commonly referred to as the “say-on-pay,” “say-on-frequency” and “say-on-golden-parachute” votes); |
•
|
are exempt from certain executive compensation disclosure provisions requiring a pay-for-performance graph and CEO pay ratio disclosure; |
•
|
may present only two years of audited financial statements and only two years of related Management’s Discussion & Analysis of Financial Condition and Results of Operations, or MD&A; and |
•
|
are eligible to claim longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act. |
Common
stock offered by us
|
shares
|
|||||
Common
stock outstanding prior to this offering
|
9,124,000 shares (1)
|
|||||
Common
stock to be outstanding after this offering
|
shares (1)(2)(3)
|
|||||
Use of
proceeds
|
Based
on an assumed initial public offering price of $ per share, we estimate that the net proceeds to us from this offering will be
approximately $13.8 million after payment of underwriting commissions and our estimated offering expenses (approximately $ million
if the underwriters exercises the over-allotment in full).
|
|||||
|
We
intend to use the proceeds from this offering to:
|
|||||
|
• promote and advertise the opportunities for consumers owning life insurance and investors to profit from participating in
the secondary market for life insurance policies;
|
|||||
|
• purchase additional life insurance policies in the secondary market;
|
|||||
|
• pay premiums on life insurance policy assets we own; and
|
|||||
|
• fund portfolio operations and for working capital purposes.
|
|||||
|
See
“Use of Proceeds” for more information.
|
|||||
Risk
factors
|
You
should read the “Risk Factors” section of this prospectus beginning on page 12 for a discussion of factors to consider carefully before
deciding to invest in shares of our common stock.
|
|||||
Proposed NASDAQ Capital Market symbol
|
GWGH
(4)
|
(1)
|
Excludes 2,000,000 shares of our common stock currently reserved for issuance under our 2013 Stock Incentive Plan, of which there are 746,500 common shares subject to outstanding incentive grants. Also excludes 831,908 common shares that are issuable upon the exercise of outstanding warrants. |
(2)
|
Includes 5,217,329 shares of our common stock to be issued immediately prior to the closing of this offering upon the automatic conversion of 3,478,219 shares of our Series A Convertible Preferred Stock that are currently issued and outstanding. |
(3)
|
Excludes an aggregate of shares of our common stock issuable upon the exercise of warrants we expect to grant to the underwriters for this offering, and excludes up to an aggregate of shares issuable to the underwriters if they exercise the over-allotment option in full, as described under “Underwriting.” |
(4)
|
We have reserved the symbol “GWGH” for purposes of listing our common stock on The NASDAQ Capital Market and expect to apply to list our common stock on such exchange. |
•
|
changes in the secondary market for life insurance; |
•
|
our limited operating history; |
•
|
the valuation of assets reflected on our financial statements; |
•
|
the reliability of assumptions underlying our actuarial models; |
•
|
the reliability of assumptions underlying our life expectancy estimates; |
•
|
our reliance on debt financing; |
•
|
risks relating to the validity and enforceability of the life insurance policies we purchase; |
•
|
our reliance on information provided and obtained by third parties; |
•
|
federal and state regulatory matters, including the effect and outcome of current regulatory investigations; |
•
|
additional expenses, not reflected in our operating history, related to being a public reporting company; |
•
|
competition in the secondary life insurance market; |
•
|
the relative illiquidity of life insurance policies; |
•
|
life insurance company credit exposure; |
•
|
economic outlook; |
•
|
performance of our investments in life insurance policies; |
•
|
financing requirements; |
•
|
litigation risks; and |
•
|
restrictive covenants contained in borrowing agreements. |
•
|
the inability to locate sufficient numbers of life insurance policy sellers and agents to source such sellers; |
•
|
the inability to convince life insurance policy owners of the benefits of selling their life insurance policy; |
•
|
competition from other companies in the life insurance secondary market; |
•
|
negative publicity about the market based on actual or perceived abuses; and |
•
|
the adoption of additional governmental regulation. |
•
|
assess the magnitude of impact that hundreds of different types of health impairments have on senior mortality on a case-by-case basis; |
•
|
apply credits and debits during the underwriting process in a manner that accounts for the different impacts of the same impairments for males and females; and |
•
|
reflect the difference in mortality between insureds who have sold policies and the group of 90,000 insureds underwritten by 21st Services, most of whom did not ultimately sell their policies in the life settlement market (such difference is frequently referred to in the life-settlement industry as “anti-selection”). |
Years Ending December 31,
|
||||||
---|---|---|---|---|---|---|
Nine months ending December 31, 2014
|
$8,323,000 | |||||
2015
|
8,638,000 | |||||
2016
|
7,193,000 | |||||
2017
|
4,252,000 | |||||
2018
|
754,000 | |||||
Thereafter
|
64,000 | |||||
|
$29,224,000 |
Years Ending December 31,
|
||||||
---|---|---|---|---|---|---|
Nine months ending December 31, 2014
|
$31,109,000 | |||||
2015
|
44,587,000 | |||||
2016
|
34,623,000 | |||||
2017
|
13,094,000 | |||||
2018
|
6,779,000 | |||||
Thereafter
|
18,873,000 | |||||
|
$149,065,000 |
•
|
are not required to obtain an attestation and report from our auditors on our management’s assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; |
•
|
are not required to provide a detailed narrative disclosure discussing our compensation principles, objectives and elements and analyzing how those elements fit with our principles and objectives (commonly referred to as “compensation discussion and analysis”); |
•
|
are not required to obtain a non-binding advisory vote from our stockholders on executive compensation or golden parachute arrangements (commonly referred to as the “say-on-pay,” “say-on-frequency” and “say-on-golden-parachute” votes); |
•
|
are exempt from certain executive compensation disclosure provisions requiring a pay-for-performance graph and CEO pay ratio disclosure; |
•
|
may present only two years of audited financial statements and only two years of related Management’s Discussion & Analysis of Financial Condition and Results of Operations, or MD&A; and |
•
|
are eligible to claim longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act. |
•
|
variations in our operating results; |
•
|
the level and quality of securities analysts’ coverage for our common stock; |
•
|
announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments; |
•
|
announcements by third parties of significant claims or proceedings against us; and |
•
|
future sales of our common stock. |
•
|
promote and advertise the opportunities for consumers owning life insurance and investors to profit from participating in the secondary market for life insurance policies; |
•
|
purchase additional life insurance policies in the secondary market; |
•
|
pay premiums on life insurance policy assets we own; and |
•
|
fund our portfolio operations and for working capital purposes. |
Year
|
Premiums
|
|||||
---|---|---|---|---|---|---|
Nine months ending December 31, 2014
|
$17,882,000 | |||||
2015
|
26,078,000 | |||||
2016
|
28,550,000 | |||||
2017
|
32,109,000 | |||||
2018
|
35,155,000 | |||||
|
$139,774,000 |
At March 31, 2014
|
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Actual
|
As
Adjusted |
||||||||||
Debt:
|
(Dollars in thousands,
except per-share amounts) (Unaudited) |
||||||||||
Renewable
Secured Debentures
|
$145,989 | $145,989 | |||||||||
Series I
Secured notes (1)
|
28,602 | 28,602 | |||||||||
Revolving
credit facility (2)
|
79,000 | 79,000 | |||||||||
Total debt
|
$253,591 | $253,591 | |||||||||
Preferred
stock:
|
|||||||||||
Series A
Convertible Preferred (par value $0.001; shares authorized 40,000,000; shares issued and outstanding 3,478,219; liquidation preference of
$26,087,000 on March 31, 2014) (3)
|
$25,036 | $ | 0 | ||||||||
Stockholders’ equity:
|
|||||||||||
Common stock
(par value $0.001 per share; shares authorized 210,000,000; shares issued and outstanding 9,124,000)
|
$ | 9 | $ | ||||||||
Additional
paid-in capital
|
2,868 | ||||||||||
Retained
earnings
|
(10,340 | ) | (10,340 | ) | |||||||
Total
stockholders’ equity
|
$(7,463 | ) | $ | ||||||||
Total debt,
preferred stock and common stockholders’ equity
|
$271,164 | $ |
(1)
|
The total outstanding face amount of Series I Secured notes outstanding at March 31, 2014 was $29,224,000, less unamortized selling costs of $622,000. The weighted-average interest rate of our outstanding Series I Secured notes at March 31, 2014 was approximately 8.35%, and the weighted-average maturity was approximately 2.24 years. |
(2)
|
The interest rate of our revolving credit line floats in conjunction with advances made thereunder. The weighted-average interest rate payable under our revolving credit line at March 31, 2014 was approximately 6.21%. Amounts owing under our revolving credit line come due on December 31, 2016. |
(3)
|
As of March 31, 2014, we had issued 3,395,000 preferred shares resulting in gross consideration of $25,261,000 (including cash proceeds, conversion of Series I Secured notes and accrued interest on Series I notes, and conversion of preferred dividends payable) net of redemptions. We incurred Series A preferred stock issuance costs of $2,838,000, of which $2,510,000 was amortized to additional paid in capital as of March 31, 2014, resulting in a carrying amount of $25,036,000. |
Public
offering price
|
$ | |||||
Pro
forma net tangible book value before offering
|
$ | |||||
Increase in pro forma net tangible book value attributable to new investors
|
$ | |||||
Pro
forma net tangible book value after offering
|
$ | |||||
Dilution in pro forma net tangible book value to new investors
|
$ |
Shares Purchased
|
Total Consideration
|
|||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number
|
Percent
|
Amount
|
Percent
|
Average
Price Per Share |
||||||||||||||||||
Existing
stockholders (1)
|
% | $ | — | —% | $ | |||||||||||||||||
New investors
|
% | $ | 100 | % | $ | |||||||||||||||||
Total
|
% | $ | 100 | % | $ |
(1)
|
Assumes the conversion of all 3,478,219 shares of our Series A Convertible Preferred Stock issued and outstanding at March 31, 2014 into an aggregate of 5,217,329 shares of our common stock at the effective time of this offering. |
March 31,
2014 |
December 31,
2013 |
December 31,
2012 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total
Assets
|
$ | 287,577,263 | $ | 275,380,476 | $ | 197,948,035 | ||||||||
Investment in Portfolio
|
254,503,535 | 234,672,794 | 164,317,183 | |||||||||||
Cash
and Cash Equivalents
|
28,083,299 | 33,449,793 | 27,497,044 | |||||||||||
Restricted Cash
|
2,853,763 | 5,832,970 | 2,093,092 | |||||||||||
Total
Liabilities
|
270,004,316 | 256,149,798 | 175,303,946 | |||||||||||
Revolving Credit Facility
|
79,000,000 | 79,000,000 | 71,000,000 | |||||||||||
Series
I Secured notes (1)
|
28,602,238 | 29,275,202 | 37,844,711 | |||||||||||
Renewable Secured Debentures (2)
|
145,989,431 | 131,646,062 | 55,718,950 | |||||||||||
Stockholder Preferred and Common Equity
|
17,572,947 | 19,530,678 | 22,644,089 |
(1)
|
The total outstanding face amount of Series I Secured notes outstanding at March 31, 2014 was $29,224,000, less unamortized selling costs of $622,000. |
(2)
|
The total outstanding face amount of Renewable Secured Debentures outstanding at March 31, 2014 was $149,065,000 plus $2,343,000 of subscriptions in process, less unamortized selling costs of $5,418,000. |
March 31,
2014 |
December 31,
2013 |
December 31,
2012 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total
Revenue
|
$ | 5,523,572 | $ | 33,064,774 | $ | 17,525,798 | ||||||||
Gain
on Life Insurance Contracts
|
5,516,205 | 29,513,642 | 17,436,743 | |||||||||||
Interest Expense
|
6,326,548 | 20,762,644 | 10,878,627 | |||||||||||
Net
Income (Loss)
|
(1,901,170 | ) | (194,955 | ) | (1,012,899 | ) |
March 31, 2014
|
December 31, 2013
|
|||||
---|---|---|---|---|---|---|
11.69%
|
11.69%
|
•
|
Policy Benefits Realized . We recognize the difference between the death benefits and carrying values of the policy when an insured event has occurred and we determine that settlement and ultimate collection of the death benefits is realizable and reasonably assured. Revenue from a transaction must meet both criteria in order to be recognized. We generally collect the face value of the life insurance policy from the insurance company within 45 days of the insured’s mortality. |
•
|
Change in Fair Value of Life Insurance Policies . We have elected to carry our investments in life insurance policies at fair value in accordance with ASC 325-30, Investments in Life Insurance Contracts . Accordingly, we value our investments in our portfolio of life insurance policies each reporting period in accordance with the fair value principles discussed herein, which includes the expected payment of premiums for future periods. |
•
|
Sale of a Life Insurance Policy or a Portfolio of Life Insurance Policies . In an event of a sale of a policy, we recognize gain or loss as the difference between the sale price and the carrying value of the policy on the date of the receipt of payment on such sale. |
•
|
Selling, General and Administrative Expenses . We recognize and record expenses incurred in the operations of the purchasing and servicing of life insurance policies. These expenses include professional fees, salaries, and sales and marketing expenditures. |
•
|
Interest Expense . We recognize and record interest expenses associated with the costs of financing our life insurance portfolio for the current period. These expenses include interest paid to our senior lender under our revolving credit facility, as well as all interest paid on our debentures and other outstanding indebtedness such as our subsidiary secured notes and dividends on convertible, redeemable preferred stock. When we issue long-term indebtedness, we amortize the issuance costs associated with such indebtedness over the outstanding term of the financing, and classify it as interest expense. |
Three months ended:
|
March 31, 2014
|
March 31, 2013
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statutory
federal income tax
|
$ | (971,000 | ) | 34.0 | % | $ | 215,000 | 34.0 | % | ||||||||||
State
income taxes, net of federal benefit
|
(143,000 | ) | 5.0 | % | 85,000 | 13.5 | % | ||||||||||||
Series A
preferred stock dividends
|
216,000 | (7.6 | )% | 216,000 | 34.1 | % | |||||||||||||
Other
permanent differences
|
(57,000 | ) | 2.0 | % | 50,000 | 7.8 | % | ||||||||||||
Total
income tax expense
|
$ | (955,000 | ) | 33.4 | % | $ | 566,000 | 89.4 | % |
Years Ending December 31,
|
||||||
---|---|---|---|---|---|---|
Nine
months ending December 31, 2014
|
$8,323,000 | |||||
2015
|
8,638,000 | |||||
2016
|
7,193,000 | |||||
2017
|
4,252,000 | |||||
2018
|
754,000 | |||||
Thereafter
|
64,000 | |||||
|
$29,224,000 |
Years Ending December 31,
|
||||||
---|---|---|---|---|---|---|
Nine
months ending December 31, 2014
|
$31,109,000 | |||||
2015
|
44,587,000 | |||||
2016
|
34,623,000 | |||||
2017
|
13,094,000 | |||||
2018
|
6,779,000 | |||||
Thereafter
|
18,873,000 | |||||
|
$149,065,000 |
Issuer/Borrower
|
Principal
Amount Outstanding |
Weighted
Average Interest Rate |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
GWG Holdings,
Inc. — Renewable Secured Debentures
|
$149,065,000 | 7.53 | % | |||||||
GWG Life
Settlements, LLC — Series I Secured notes
|
29,224,000 | 8.35 | % | |||||||
GWG DLP
Funding II, LLC — Revolving credit facility
|
79,000,000 | 6.21 | % | |||||||
Total
|
$257,289,000 | 7.21 | % |
Portfolio Discount Rate
|
11%
|
12%
|
13%
|
14%
|
15%
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Value of
portfolio
|
$263,696,606 | $250,538,024 | $238,394,725 | $227,165,747 | $216,762,110 | |||||||||||||||||
Cash and cash
equivalents
|
30,937,062 | 30,937,062 | 30,937,062 | 30,937,062 | 30,937,062 | |||||||||||||||||
Total assets
|
294,633,668 | 281,475,086 | 269,331,787 | 258,102,808 | 247,699,172 | |||||||||||||||||
Revolving
credit facility Autobahn/DZ Bank
|
79,000,000 | 79,000,000 | 79,000,000 | 79,000,000 | 79,000,000 | |||||||||||||||||
Net after
revolving credit facility
|
215,633,668 | 202,475,086 | 190,331,787 | 179,102,808 | 168,699,172 | |||||||||||||||||
Series I
Secured notes and Renewable Secured Debentures
|
178,289,219 | 178,289,219 | 178,289,219 | 178,289,219 | 178,289,219 | |||||||||||||||||
Net after
Series I Secured notes and Renewable Secured Debentures
|
37,344,449 | 24,185,867 | 12,042,568 | 813,590 | (9,590,047 | ) | ||||||||||||||||
Impairment to
Series I Secured notes and Renewable Secured Debentures
|
No
impairment |
No
impairment |
No
impairment |
No
impairment |
Impairment
|
Quarter End Date
|
Portfolio
Face Amount |
12-Month
Trailing Benefits Collected |
12-Month
Trailing Premiums Paid |
12-Month
Trailing Benefits/Premium Coverage Ratio |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
March 31,
2012
|
$ | 482,455,000 | $ | 4,203,000 | $ | 14,977,000 | 28.06 | % | ||||||||||
June 30, 2012
|
489,255,000 | 8,703,000 | 15,412,000 | 56.47 | % | |||||||||||||
September 30,
2012
|
515,661,000 | 7,833,000 | 15,837,000 | 49.46 | % | |||||||||||||
December 31,
2012
|
572,245,000 | 7,350,000 | 16,597,000 | 44.28 | % | |||||||||||||
March 31,
2013
|
639,755,000 | 11,350,000 | 18,044,000 | 62.90 | % | |||||||||||||
June 30, 2013
|
650,655,000 | 13,450,000 | 19,182,000 | 70.11 | % | |||||||||||||
September 30,
2013
|
705,069,000 | 18,450,000 | 20,279,000 | 90.98 | % | |||||||||||||
December 31,
2013
|
740,648,000 | 16,600,000 | 21,733,000 | 76.38 | % | |||||||||||||
March 31,
2014
|
771,940,000 | 12,600,000 | 21,930,000 | 57.46 | % |
Year
|
Premiums and
Servicing |
|||||
---|---|---|---|---|---|---|
Nine
months ending December 31, 2014
|
$ 18,025,000 | |||||
2015
|
26,221,000 | |||||
2016
|
28,693,000 | |||||
2017
|
32,252,000 | |||||
2018
|
35,298,000 | |||||
Total
|
$140,489,000 |
Nine
months ending December 31, 2014
|
$78,000 | |||||
2015
|
$ | 70,000 | ||||
Total
|
$148,000 |
Three months ended March 31,
|
2014
|
2013
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|
GAAP net
gain (loss)
|
$(1,901,000 | ) | $67,000 | |||||||
Unrealized
fair value gain (1)
|
(11,359,000 | ) | (11,495,000 | ) | ||||||
Adjusted cost
basis increase (2)
|
11,397,000 | 10,256,000 | ||||||||
Accrual of
unrealized actuarial gain (3)
|
7,305,000 | 5,033,000 | ||||||||
Total
adjusted non-GAAP income (4)
|
$5,442,000 | $3,861,000 |
(1)
|
Reversal of unrealized fair value gain of life insurance policies for current period. |
(2)
|
Adjusted cost basis is increased to include those acquisition and servicing expenses that are not capitalized by GAAP. |
(3)
|
Accrual of actuarial gain at expected internal rate of return based on investment cost basis for the period. |
(4)
|
We must maintain an annual positive consolidated net income, calculated on a non-GAAP basis, to maintain compliance with our revolving credit facility with DZ Bank/Autobahn. |
As of
March 31, 2014 |
As of
December 31, 2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
GAAP net
worth (1)
|
$17,573,000 | $19,231,000 | ||||||||
Less
intangible assets (2)
|
(7,179,000 | ) | (6,068,000 | ) | ||||||
GAAP tangible
net worth
|
10,394,000 | 13,163,000 | ||||||||
Unrealized
fair value gain (3)
|
(126,103,000 | ) | (114,744,000 | ) | ||||||
Adjusted cost
basis increase (4)
|
117,602,000 | 106,201,000 | ||||||||
Accrual of
unrealized actuarial gain (5)
|
56,972,000 | 49,666,000 | ||||||||
Total
adjusted non-GAAP tangible net worth (6)
|
$58,865,000 | $54,286,000 |
(1)
|
Includes termination of redeemable member’s interest prior to corporate conversion and preferred stock classified as temporary equity. |
(2)
|
Unamortized portion of deferred financing costs and pre-paid insurance. |
(3)
|
Reversal of cumulative unrealized fair value gain or loss of life insurance policies. |
(4)
|
Adjusted cost basis is increased by acquisition and servicing expenses which are not capitalized under GAAP. |
(5)
|
Accrual of cumulative actuarial gain at expected internal rate of return based on investment cost basis. |
(6)
|
We must maintain a total adjusted non-GAAP tangible net worth of $15 million to maintain compliance with our revolving credit facility with DZ Bank/Autobahn. |
As of
March 31, 2014 |
As of
December 31, 2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Weighted-average expected IRR (1)
|
12.17 | % | 12.21 | % | ||||||
Weighted-average revolving credit facility interest rate (2)
|
6.21 | % | 6.19 | % | ||||||
Excess spread
(3)
|
5.96 | % | 6.02 | % | ||||||
Total
weighted-average interest rate on indebtedness for borrowed money (4)
|
7.21 | % | 7.20 | % | ||||||
Total excess
spread
|
4.96 | % | 5.01 | % |
(1)
|
This represents the weighted-average expected internal rate of return of the life insurance policies as of the measurement date based upon our investment cost basis in the insurance policies and expected cash flows from the life insurance portfolio. Our investment cost basis is calculated as our cash investment in the life insurance policies, without regard to GAAP-based fair value measurements, and is set forth below: |
Investment Cost
Basis
|
As of
March 31, 2014 |
As of
December 31, 2013 |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
GAAP fair
value
|
$254,504,000 | $234,673,000 | ||||||||
Unrealized
fair value gain (A)
|
(126,103,000 | ) | (114,744,000 | ) | ||||||
Adjusted cost
basis increase (B)
|
117,602,000 | 106,201,000 | ||||||||
Investment
cost basis (C)
|
$246,003,000 | $226,130,000 |
(A)
|
This represents the reversal of cumulative unrealized GAAP fair value gain of life insurance policies. |
(B)
|
Adjusted cost basis is increased to include those acquisition and servicing expenses that are not capitalized by GAAP. |
(C)
|
This is the full cash investment cost basis in life insurance policies from which our expected internal rate of return is calculated. |
(2)
|
This is the weighted-average revolving credit facility interest rate as of the measurement date. |
(3)
|
We must maintain an excess spread of 2.00% relating to our revolving credit facility to maintain compliance under such facility. |
(4)
|
Represents the weighted-average interest rate paid on all outstanding indebtedness as of the measurement date, determined as follows: |
Outstanding
Indebtedness
|
As of
March 31, 2014 |
As of
December 31, 2013 |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Revolving
credit facility
|
$ | 79,000,000 | $ | 79,000,000 | ||||||
Series I
Secured notes
|
29,224,000 | 29,744,000 | ||||||||
Renewable
Secured Debentures
|
149,065,000 | 134,891,000 | ||||||||
Total
|
$ | 257,289,000 | $ | 243,635,000 | ||||||
Interest Rates on Indebtedness
|
||||||||||
Revolving
credit facility
|
6.21 | % | 6.19 | % | ||||||
Series I
Secured notes
|
8.35 | % | 8.35 | % | ||||||
Renewable
Secured Debentures
|
7.53 | % | 7.53 | % | ||||||
Weighted-average interest rates on indebtedness
|
7.21 | % | 7.20 | % |
As of
March 31, 2014 |
As of
December 31, 2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Life
insurance portfolio policy benefits
|
$771,940,000 | $740,648,000 | ||||||||
Discount rate
of future cash flows
|
7.21 | % | 7.20 | % | ||||||
Net present
value of Life insurance portfolio policy benefits
|
$325,006,000 | $302,761,000 | ||||||||
Cash and cash
equivalents
|
30,937,000 | 39,283,000 | ||||||||
Total
Coverage
|
355,943,000 | 332,044,000 | ||||||||
Revolving
credit facility
|
79,000,000 | 79,000,000 | ||||||||
Series I
Secured notes
|
29,224,000 | 29,744,000 | ||||||||
Renewable
Secured Debentures
|
149,065,000 | 134,891,000 | ||||||||
Total
Indebtedness
|
$257,289,000 | $243,635,000 | ||||||||
Debt Coverage
Ratio
|
72.28 | % | 71.23 | % | ||||||
Subordination
Ratio
|
22.19 | % | 23.10 | % |
•
|
purchasing life insurance policies with expected internal rates of returns in excess of our cost of capital; |
•
|
paying the premiums and costs associated with the life insurance policy until the insured’s mortality; |
•
|
obtaining a large and diverse portfolio to mitigate actuarial risk; |
•
|
maintaining diversified funding sources to reduce our overall cost of financing; |
•
|
engaging in hedging strategies that reduce potential volatility to our cost of financing; and |
•
|
maintaining rigorous portfolio monitoring and servicing practices. |
•
|
Industry Experience : We have actively participated in the development of the secondary market of life insurance as a principal purchaser and financier since 2006. Our position within the marketplace has allowed us to evaluate over 36,000 life insurance policies for possible purchase, thereby gaining a deep understanding of the variety of issues involved when purchasing life insurance policies in the secondary market. We have participated in the leadership of various industry associations and forums, including the Life Insurance Settlement Association (LISA) and the Insurance Studies Institute (ISI). Our experience gives us confidence in building a portfolio of life insurance policies that will perform to our expectations. |
•
|
Operational Platform : We have built an operational platform and systems for efficiently tracking, processing and servicing life insurance policies that we believe provide competitive advantages when purchasing policies in the secondary marketplace, and servicing the policies once acquired. |
•
|
Origination and Underwriting Practices : We seek to purchase life insurance policies that meet published guidelines on what policies would be accepted in a rated securitization. We purchase only permanent life insurance policies we consider to be non-contestable and that meet stringent underwriting criteria and reviews. We consider a life insurance policy to be “non-contestable” once applicable state law prohibits the insurer from challenging the validity of the policy due to fraud. In this regard, state non-contestability laws generally require a period of one to two years to elapse after the initial issuance of the policy before that policy is considered non-contestable under state law. Non-contestability laws do not, however, prevent an insurer from challenging the validity of a policy procured by fraud for lack of an insurable interest at the time at which the policy was purchased (such as is the case with “stranger-originated” life insurance policies). |
•
|
Origination Relationships : We have established origination relationships with over 300 life insurance policy brokers and insurance agents who submit policies for our purchase or financing. Our referral base knows our underwriting standards for purchasing life insurance policies in the secondary market, which provides confidence in our bidding and closing processes and streamlines our own due-diligence process. We expect to expand our origination relationships and channels with the proceeds of this offering. |
•
|
Life Expectancy Methodology : We generally rely on two life expectancy estimates from independent third-party medical-actuarial underwriting firms to develop our own life expectancy estimate. For a majority of our life insurance policy purchases, we rely on estimates obtained from 21st Services and AVS Underwriting to develop our life expectancy estimate. We may also obtain life expectancy estimates from Fasano Associates and Examination Management Services, Inc. |
•
|
Pricing Software and Methodology : We use actuarial pricing methodologies and software tools that are built and supported by leading independent actuarial service firms such as Modeling Actuarial Pricing Systems, Inc. (“MAPS”) for calculating our expected returns. |
•
|
Diversified Funding : We have actively developed diversified sources for accessing capital markets in support of our buy-and-hold strategy for our portfolio of life insurance policies, ranging from institutional bank financing to a network of broker-dealers registered with the Financial Industry Regulatory Authority (“FINRA”), many of whom have participated in one or more of our Series I Secured note financing, our Series A preferred stock financing, or our Renewable Secured Debenture |
|
financing. If in the future we determine to offer different kinds of investment products, we expect to leverage the network of broker-dealers that we have built over time. |
•
|
Relatively New Market : The purchase and ownership of life insurance policies acquired in the secondary market is a relatively new and evolving market. Our ability to source and purchase life insurance policies at attractive discounts materially depends on the continued development of the secondary market for life insurance. This includes the solvency of the life insurance companies that pay the face value of the life insurance benefits, the accuracy of life expectancy assumptions, and other factors beyond our control. |
•
|
Assumptions About Valuation of Our Assets : The valuation of our portfolio of life insurance policies, which is the principal asset on our balance sheet, requires us to make material assumptions that may ultimately prove to be incorrect. These assumptions include appropriate discount rates, cash flow projections, and actuarial life expectancies, any of which may ultimately prove to be inaccurate. |
•
|
Ability to Expand Our Portfolio : Our business model relies on achieving actual results that are in line with the results we expect to attain from our investments in life insurance policy assets. In this regard, we believe that the larger the portfolio of life insurance policies we own, the greater likelihood we will achieve actuarial results matching our expected results. Although we plan to expand the number of life insurance policies we own using proceeds raised from the sale of our Renewable Secured Debentures and our common stock in this offering, we may be unable to meet this goal. And, even if we attain the goal, we may not achieve the actuarial results we expect. |
•
|
Reliance on Financing : To date, we have chosen to finance our business almost entirely through the issuance of debt, including the sale of Renewable Secured Debentures, Series I Secured notes, and a senior revolving credit facility. Our business model expects that we will have continued access to financing in order to purchase a large and diversified portfolio of life insurance policies, and thereafter pay the attendant premiums and servicing costs of maintaining that portfolio. In building a larger portfolio of policies, our goal is to remain diversified in terms of insurance carriers and the medical conditions of insureds. We believe that diversification among insurers and medical conditions will lower our overall risk, and that a larger number of policies will provide our portfolio with greater actuarial stability. We will be required to rely on our access to financing until such time as we experience a significant amount of mortality within our portfolio and begin receiving significant revenues from the receipt of insurance policy benefits. Nevertheless, we may not receive insurance policy benefits that match our cash flow projections. |
•
|
Risk of Investment in Life Insurance Policies : Our investments in life insurance policies have inherent risks, including fraud and legal challenges to the validity of the policies, as well as the possibility that the seller of the policy may have provided us with inaccurate or misleading information. |
•
|
Effects of Regulation : Our business is subject to complex state regulation. Changes in state laws and regulations governing our business, or changes in the interpretation of such laws and regulations, could negatively affect our business. |
Total
portfolio face value of policy benefits
|
$771,940,000 | |||||
Average
face value per policy
|
$2,699,000 | |||||
Average face value per insured life
|
$3,015,000 | |||||
Average age of insured (yrs.)*
|
82.3 | |||||
Average
life expectancy estimate (yrs.)*
|
7.02 | |||||
Total
number of policies
|
286 | |||||
Number of unique lives
|
256 | |||||
Demographics
|
67% Males; 33% Females
|
|||||
Number of
smokers
|
3 insureds are smokers
|
|||||
Largest
policy as % of total portfolio
|
1.30 | % | ||||
Average
policy as % of total portfolio
|
0.35 | % | ||||
Average
Annual Premium as % of face value
|
3.15 | % |
*
|
Averages presented in the table are weighted averages. |
Min
Age |
Max
Age |
Policy
Benefits |
Weighted
Average Life Expectancy (yrs.) |
Distribution
|
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
65
|
69 | $11,156,000 | 8.27 | 1.45 | % | |||||||||||||
70
|
74 | 43,617,000 | 9.16 | 5.65 | % | |||||||||||||
75
|
79 | 178,198,000 | 8.57 | 23.08 | % | |||||||||||||
80
|
84 | 293,719,000 | 7.44 | 38.05 | % | |||||||||||||
85
|
89 | 219,929,000 | 5.08 | 28.49 | % | |||||||||||||
90
|
95 | 25,321,000 | 3.95 | 3.28 | % | |||||||||||||
Total
|
$771,940,000 | 7.02 | 100.00 | % |
Min
Age |
Max
Age |
Policies
|
Weighted
Average Life Expectancy (yrs.) |
Distribution
|
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
65
|
69 | 8 | 8.27 | 2.80 | % | |||||||||||||
70
|
74 | 19 | 9.16 | 6.64 | % | |||||||||||||
75
|
79 | 59 | 8.57 | 20.63 | % | |||||||||||||
80
|
84 | 104 | 7.44 | 36.36 | % | |||||||||||||
85
|
89 | 84 | 5.08 | 29.37 | % | |||||||||||||
90
|
95 | 12 | 3.95 | 4.20 | % | |||||||||||||
Total
|
286 | 7.02 | 100.00 | % |
Min LE (Months)
|
Max LE (Months)
|
Policy Benefits
|
Distribution
|
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
144
|
169 | $5,000,000 | 0.65 | % | ||||||||||
120
|
143 | 106,656,000 | 13.82 | % | ||||||||||
96
|
119 | 163,139,000 | 21.13 | % | ||||||||||
72
|
95 | 203,321,000 | 26.34 | % | ||||||||||
48
|
71 | 195,658,000 | 25.34 | % | ||||||||||
16
|
47 | 98,166,000 | 12.72 | % | ||||||||||
Total
|
$771,940,000 | 100.00 | % |
Primary Disease Category
|
Policy Benefits
|
Distribution
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Cancer
|
$49,967,000 | 6.47 | % | |||||||
Cardiovascular
|
154,068,000 | 19.96 | % | |||||||
Cerebrovascular
|
36,985,000 | 4.79 | % | |||||||
Dementia
|
53,949,000 | 6.99 | % | |||||||
Diabetes
|
39,067,000 | 5.06 | % | |||||||
Multiple
|
195,051,000 | 25.27 | % | |||||||
Neurological
Disorders
|
13,000,000 | 1.68 | % | |||||||
No Disease
|
69,986,000 | 9.07 | % | |||||||
Other
|
108,167,000 | 14.01 | % | |||||||
Respiratory
Diseases
|
51,700,000 | 6.70 | % | |||||||
Total Policy
Benefits
|
$771,940,000 | 100.00 | % |
Face Amount
|
Gender
|
Age (ALB)(1)
|
LE(2)
|
Carrier
|
S&P
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | $ | 4,000,000 | M | 93 | 38.9 | MetLife Investors USA Insurance Company | AA- | |||||||||||||||||||||
2 | $ | 1,100,000 | M | 93 | 33.1 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
3 | $ | 1,770,726 | F | 93 | 37.2 | Aviva Life Insurance Company | N/A | |||||||||||||||||||||
4 | $ | 1,000,000 | F | 92 | 43.5 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
5 | $ | 3,200,000 | M | 92 | 66.7 | West Coast Life Insurance Company | AA- | |||||||||||||||||||||
6 | $ | 250,000 | M | 91 | 26.1 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
7 | $ | 2,500,000 | M | 90 | 29.7 | Columbus Life Insurance Company | AA | |||||||||||||||||||||
8 | $ | 3,000,000 | M | 90 | 59.3 | West Coast Life Insurance Company | AA- | |||||||||||||||||||||
9 | $ | 500,000 | M | 90 | 25.3 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
10 | $ | 5,000,000 | F | 90 | 63.7 | American General Life Insurance Company | A+ | |||||||||||||||||||||
11 | $ | 2,000,000 | F | 90 | 24.6 | Pruco Life Insurance Company | AA- | |||||||||||||||||||||
12 | $ | 1,000,000 | F | 90 | 41.1 | Protective Life Insurance Company | AA- | |||||||||||||||||||||
13 | $ | 1,682,773 | F | 89 | 62.1 | Hartford Life and Annuity Insurance Company | BBB+ | |||||||||||||||||||||
14 | $ | 5,000,000 | M | 89 | 42.1 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
15 | $ | 1,000,000 | M | 89 | 37.8 | State Farm Life Insurance Company | AA- | |||||||||||||||||||||
16 | $ | 5,000,000 | F | 89 | 43.9 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
17 | $ | 1,000,000 | M | 89 | 16.3 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
18 | $ | 1,000,000 | F | 88 | 62.1 | United of Omaha Life Insurance Company | A+ | |||||||||||||||||||||
19 | $ | 3,500,000 | F | 88 | 67.7 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
20 | $ | 3,100,000 | F | 88 | 44.8 | Lincoln Benefit Life Company | BBB+ | |||||||||||||||||||||
21 | $ | 1,500,000 | F | 88 | 75.9 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
22 | $ | 1,750,000 | M | 88 | 32.0 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
23 | $ | 2,500,000 | F | 88 | 18.3 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
24 | $ | 2,500,000 | F | 88 | 18.3 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
25 | $ | 3,000,000 | F | 88 | 44.3 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
26 | $ | 500,000 | F | 88 | 36.8 | Genworth Life Insurance Company | A- | |||||||||||||||||||||
27 | $ | 1,000,000 | F | 88 | 36.8 | Genworth Life Insurance Company | A- | |||||||||||||||||||||
28 | $ | 1,000,000 | F | 88 | 36.8 | Genworth Life Insurance Company | A- | |||||||||||||||||||||
29 | $ | 500,000 | F | 88 | 36.8 | Genworth Life Insurance Company | A- | |||||||||||||||||||||
30 | $ | 5,000,000 | F | 88 | 51.2 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
31 | $ | 5,000,000 | F | 88 | 28.4 | Lincoln National Life Insurance Company | AA- | |||||||||||||||||||||
32 | $ | 715,000 | F | 88 | 71.7 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
33 | $ | 1,203,520 | M | 88 | 54.7 | Columbus Life Insurance Company | AA | |||||||||||||||||||||
34 | $ | 1,350,000 | F | 88 | 46.7 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
35 | $ | 2,000,000 | F | 88 | 40.2 | American General Life Insurance Company | A+ | |||||||||||||||||||||
36 | $ | 600,000 | F | 88 | 31.9 | Columbus Life Insurance Company | AA | |||||||||||||||||||||
37 | $ | 5,000,000 | F | 87 | 57.4 | Massachusetts Mutual Life Insurance Company | AA+ | |||||||||||||||||||||
38 | $ | 2,500,000 | F | 87 | 59.3 | American General Life Insurance Company | A+ | |||||||||||||||||||||
39 | $ | 2,500,000 | M | 87 | 50.1 | Pacific Life Insurance Company | A+ | |||||||||||||||||||||
40 | $ | 5,000,000 | M | 87 | 64.8 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
41 | $ | 1,500,000 | M | 87 | 50.3 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
42 | $ | 1,500,000 | M | 87 | 50.3 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
43 | $ | 1,000,000 | F | 87 | 77.9 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
44 | $ | 250,000 | F | 87 | 77.9 | Transamerica Life Insurance Company | AA- |
Face Amount
|
Gender
|
Age (ALB)(1)
|
LE(2)
|
Carrier
|
S&P
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
45 | $ | 500,000 | M | 87 | 73.1 | Lincoln National Life Insurance Company | AA- | |||||||||||||||||||||
46 | $ | 4,785,380 | F | 87 | 52.1 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
47 | $ | 8,985,000 | M | 87 | 42.5 | Massachusetts Mutual Life Insurance Company | AA+ | |||||||||||||||||||||
48 | $ | 1,803,455 | F | 87 | 60.7 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
49 | $ | 1,529,270 | F | 87 | 60.7 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
50 | $ | 5,000,000 | M | 87 | 63.5 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
51 | $ | 2,225,000 | F | 87 | 84.9 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
52 | $ | 3,000,000 | F | 87 | 94.0 | Massachusetts Mutual Life Insurance Company | AA+ | |||||||||||||||||||||
53 | $ | 1,500,000 | M | 87 | 57.2 | Union Central Life Insurance Company | A+ | |||||||||||||||||||||
54 | $ | 100,000 | M | 87 | 34.2 | Protective Life Insurance Company | AA- | |||||||||||||||||||||
55 | $ | 100,000 | M | 87 | 34.2 | Protective Life Insurance Company | AA- | |||||||||||||||||||||
56 | $ | 100,000 | M | 87 | 34.2 | Protective Life Insurance Company | AA- | |||||||||||||||||||||
57 | $ | 3,500,000 | F | 87 | 52.7 | Lincoln National Life Insurance Company | AA- | |||||||||||||||||||||
58 | $ | 3,000,000 | M | 87 | 44.1 | American General Life Insurance Company | A+ | |||||||||||||||||||||
59 | $ | 500,000 | F | 86 | 80.5 | Sun Life Assurance Company of Canada (U.S.) | BBB | |||||||||||||||||||||
60 | $ | 5,000,000 | F | 86 | 45.9 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
61 | $ | 3,000,000 | M | 86 | 64.7 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
62 | $ | 250,000 | M | 86 | 84.0 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
63 | $ | 6,000,000 | F | 86 | 68.0 | Sun Life Assurance Company of Canada (U.S.) | BBB | |||||||||||||||||||||
64 | $ | 4,000,000 | F | 86 | 84.5 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
65 | $ | 5,570,000 | F | 86 | 59.2 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
66 | $ | 5,570,000 | F | 86 | 59.2 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
67 | $ | 1,000,000 | F | 86 | 46.7 | New York Life Insurance Company | AA+ | |||||||||||||||||||||
68 | $ | 5,000,000 | F | 86 | 42.2 | Penn Mutual Life Insurance Company | A+ | |||||||||||||||||||||
69 | $ | 1,000,000 | M | 86 | 66.3 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
70 | $ | 10,000,000 | F | 86 | 84.3 | West Coast Life Insurance Company | AA- | |||||||||||||||||||||
71 | $ | 2,500,000 | M | 86 | 59.2 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
72 | $ | 1,000,000 | F | 86 | 63.0 | West Coast Life Insurance Company | AA- | |||||||||||||||||||||
73 | $ | 2,000,000 | F | 86 | 63.0 | West Coast Life Insurance Company | AA- | |||||||||||||||||||||
74 | $ | 800,000 | M | 86 | 67.0 | National Western Life Insurance Company | A | |||||||||||||||||||||
75 | $ | 200,000 | M | 86 | 59.7 | Lincoln Benefit Life Company | BBB+ | |||||||||||||||||||||
76 | $ | 4,445,467 | M | 86 | 70.1 | Penn Mutual Life Insurance Company | A+ | |||||||||||||||||||||
77 | $ | 7,500,000 | M | 86 | 62.0 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
78 | $ | 3,600,000 | F | 86 | 69.7 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
79 | $ | 1,000,000 | F | 86 | 38.2 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
80 | $ | 4,513,823 | F | 86 | 33.8 | Aviva Life Insurance Company | N/A | |||||||||||||||||||||
81 | $ | 2,000,000 | M | 86 | 50.5 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
82 | $ | 2,000,000 | F | 86 | 86.9 | U.S. Financial Life Insurance Company | A+ | |||||||||||||||||||||
83 | $ | 1,000,000 | M | 85 | 72.4 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
84 | $ | 2,000,000 | M | 85 | 72.4 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
85 | $ | 5,000,000 | M | 85 | 60.1 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
86 | $ | 1,200,000 | M | 85 | 71.6 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
87 | $ | 1,000,000 | F | 85 | 96.8 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
88 | $ | 3,000,000 | M | 85 | 96.5 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
89 | $ | 8,500,000 | M | 85 | 93.1 | Massachusetts Mutual Life Insurance Company | AA+ | |||||||||||||||||||||
90 | $ | 1,000,000 | M | 85 | 35.5 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
91 | $ | 500,000 | M | 85 | 94.0 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
92 | $ | 500,000 | F | 85 | 67.5 | Beneficial Life Insurance Company | N/A | |||||||||||||||||||||
93 | $ | 5,000,000 | M | 85 | 93.3 | Lincoln National Life Insurance Company | AA- | |||||||||||||||||||||
94 | $ | 2,000,000 | M | 85 | 111.5 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
95 | $ | 2,000,000 | M | 85 | 111.5 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
96 | $ | 2,000,000 | M | 85 | 111.5 | ING Life Insurance and Annuity Company | A- |
Face Amount
|
Gender
|
Age (ALB)(1)
|
LE(2)
|
Carrier
|
S&P
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
97 | $ | 1,365,000 | F | 84 | 97.3 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
98 | $ | 1,000,000 | M | 84 | 50.9 | Massachusetts Mutual Life Insurance Company | AA+ | |||||||||||||||||||||
99 | $ | 3,750,000 | M | 84 | 87.4 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
100 | $ | 2,000,000 | M | 84 | 96.7 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
101 | $ | 1,000,000 | M | 84 | 71.6 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
102 | $ | 2,000,000 | F | 84 | 97.4 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
103 | $ | 3,000,000 | F | 84 | 96.1 | Sun Life Assurance Company of Canada (U.S.) | BBB | |||||||||||||||||||||
104 | $ | 2,328,547 | M | 84 | 55.5 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
105 | $ | 2,000,000 | M | 84 | 55.5 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
106 | $ | 2,000,000 | M | 84 | 73.4 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
107 | $ | 1,500,000 | M | 84 | 60.4 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
108 | $ | 1,500,000 | M | 84 | 60.4 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
109 | $ | 3,000,000 | F | 84 | 83.3 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
110 | $ | 5,000,000 | M | 84 | 85.1 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
111 | $ | 1,000,000 | M | 84 | 58.6 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
112 | $ | 1,800,000 | M | 84 | 62.6 | John Hancock Variable Life Insurance Company | AA- | |||||||||||||||||||||
113 | $ | 5,000,000 | F | 84 | 105.1 | American General Life Insurance Company | A+ | |||||||||||||||||||||
114 | $ | 2,000,000 | M | 84 | 73.3 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
115 | $ | 1,750,000 | M | 84 | 73.3 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
116 | $ | 2,000,000 | M | 84 | 45.5 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
117 | $ | 1,425,000 | M | 84 | 95.1 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
118 | $ | 5,000,000 | F | 83 | 109.4 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
119 | $ | 1,000,000 | F | 83 | 96.0 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
120 | $ | 6,000,000 | F | 83 | 123.3 | American General Life Insurance Company | A+ | |||||||||||||||||||||
121 | $ | 1,500,000 | M | 83 | 60.4 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
122 | $ | 1,500,000 | F | 83 | 121.6 | Lincoln Benefit Life Company | BBB+ | |||||||||||||||||||||
123 | $ | 4,000,000 | M | 83 | 47.5 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
124 | $ | 1,000,000 | M | 83 | 94.0 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
125 | $ | 2,000,000 | F | 83 | 111.2 | Lincoln Benefit Life Company | BBB+ | |||||||||||||||||||||
126 | $ | 1,000,000 | M | 83 | 65.6 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
127 | $ | 2,700,000 | M | 83 | 73.5 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
128 | $ | 829,022 | F | 83 | 35.7 | Hartford Life and Annuity Insurance Company | BBB+ | |||||||||||||||||||||
129 | $ | 1,500,000 | M | 83 | 91.4 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
130 | $ | 5,000,000 | M | 83 | 101.4 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
131 | $ | 7,600,000 | F | 83 | 109.8 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
132 | $ | 2,500,000 | F | 83 | 74.5 | American General Life Insurance Company | A+ | |||||||||||||||||||||
133 | $ | 2,500,000 | M | 83 | 71.2 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
134 | $ | 3,000,000 | M | 83 | 71.2 | Lincoln National Life Insurance Company | AA- | |||||||||||||||||||||
135 | $ | 500,000 | M | 83 | 51.7 | Genworth Life Insurance Company | A- | |||||||||||||||||||||
136 | $ | 4,000,000 | F | 83 | 55.4 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
137 | $ | 3,000,000 | F | 83 | 54.8 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
138 | $ | 1,703,959 | M | 83 | 79.4 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
139 | $ | 500,000 | M | 83 | 27.7 | Great Southern Life Insurance Company | N/A | |||||||||||||||||||||
140 | $ | 1,000,000 | M | 83 | 69.7 | Hartford Life and Annuity Insurance Company | BBB+ | |||||||||||||||||||||
141 | $ | 3,500,000 | F | 83 | 120.5 | Lincoln Benefit Life Company | BBB+ | |||||||||||||||||||||
142 | $ | 5,000,000 | M | 82 | 77.5 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
143 | $ | 500,000 | M | 82 | 113.2 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
144 | $ | 2,000,000 | M | 82 | 50.5 | National Life Insurance Company | A | |||||||||||||||||||||
145 | $ | 4,200,000 | F | 82 | 140.3 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
146 | $ | 750,000 | M | 82 | 101.2 | West Coast Life Insurance Company | AA- | |||||||||||||||||||||
147 | $ | 5,000,000 | M | 82 | 85.5 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
148 | $ | 5,000,000 | M | 82 | 86.7 | Jefferson-Pilot Life Insurance Company | AA- |
Face Amount
|
Gender
|
Age (ALB)(1)
|
LE(2)
|
Carrier
|
S&P
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
149 | $ | 1,500,000 | M | 82 | 87.4 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
150 | $ | 3,500,000 | F | 82 | 116.9 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
151 | $ | 3,000,000 | F | 82 | 106.8 | MetLife Investors USA Insurance Company | AA- | |||||||||||||||||||||
152 | $ | 4,500,000 | M | 82 | 86.2 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
153 | $ | 2,275,000 | M | 82 | 103.6 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
154 | $ | 2,000,000 | M | 82 | 98.2 | Pacific Life Insurance Company | A+ | |||||||||||||||||||||
155 | $ | 3,500,000 | M | 82 | 84.5 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
156 | $ | 3,000,000 | M | 82 | 72.9 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
157 | $ | 1,500,000 | M | 82 | 34.9 | Pacific Life Insurance Company | A+ | |||||||||||||||||||||
158 | $ | 2,000,000 | F | 82 | 111.1 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
159 | $ | 10,000,000 | F | 82 | 68.3 | American National Insurance Company | A | |||||||||||||||||||||
160 | $ | 500,000 | M | 82 | 34.6 | West Coast Life Insurance Company | AA- | |||||||||||||||||||||
161 | $ | 3,500,000 | F | 81 | 105.4 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
162 | $ | 1,000,000 | M | 81 | 80.9 | Lincoln National Life Insurance Company | AA- | |||||||||||||||||||||
163 | $ | 3,000,000 | M | 81 | 51.1 | U.S. Financial Life Insurance Company | A+ | |||||||||||||||||||||
164 | $ | 1,500,000 | M | 81 | 67.2 | Pacific Life Insurance Company | A+ | |||||||||||||||||||||
165 | $ | 5,000,000 | M | 81 | 123.4 | American General Life Insurance Company | A+ | |||||||||||||||||||||
166 | $ | 1,900,000 | M | 81 | 77.9 | American National Insurance Company | A | |||||||||||||||||||||
167 | $ | 500,000 | M | 81 | 56.6 | New York Life Insurance Company | AA+ | |||||||||||||||||||||
168 | $ | 500,000 | M | 81 | 56.6 | New York Life Insurance Company | AA+ | |||||||||||||||||||||
169 | $ | 250,000 | M | 81 | 42.7 | Jackson National Life Insurance Company | AA | |||||||||||||||||||||
170 | $ | 5,000,000 | F | 81 | 87.6 | Sun Life Assurance Company of Canada (U.S.) | BBB | |||||||||||||||||||||
171 | $ | 750,000 | M | 81 | 94.3 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
172 | $ | 1,995,000 | F | 81 | 93.4 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
173 | $ | 4,000,000 | M | 81 | 68.3 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
174 | $ | 1,250,000 | F | 81 | 73.3 | Columbus Life Insurance Company | AA | |||||||||||||||||||||
175 | $ | 10,000,000 | M | 81 | 91.5 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
176 | $ | 2,300,000 | M | 81 | 30.3 | American General Life Insurance Company | A+ | |||||||||||||||||||||
177 | $ | 6,217,200 | F | 81 | 119.3 | Phoenix Life Insurance Company | BB- | |||||||||||||||||||||
178 | $ | 2,500,000 | F | 81 | 84.5 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
179 | $ | 5,000,000 | F | 81 | 69.4 | Massachusetts Mutual Life Insurance Company | AA+ | |||||||||||||||||||||
180 | $ | 5,000,000 | M | 81 | 88.3 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
181 | $ | 350,000 | M | 81 | 46.7 | Reassure America Life Insurance Company | AA | |||||||||||||||||||||
182 | $ | 5,000,000 | M | 81 | 96.2 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
183 | $ | 3,000,000 | M | 80 | 80.2 | Protective Life Insurance Company | AA- | |||||||||||||||||||||
184 | $ | 1,500,000 | M | 80 | 80.2 | American General Life Insurance Company | A+ | |||||||||||||||||||||
185 | $ | 2,000,000 | F | 80 | 130.2 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
186 | $ | 5,000,000 | M | 80 | 106.2 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
187 | $ | 550,000 | M | 80 | 118.2 | Genworth Life Insurance Company | A- | |||||||||||||||||||||
188 | $ | 1,680,000 | F | 80 | 81.3 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
189 | $ | 1,000,000 | F | 80 | 111.8 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
190 | $ | 1,250,000 | M | 80 | 115.2 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
191 | $ | 1,000,000 | M | 80 | 79.5 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
192 | $ | 1,250,000 | F | 80 | 89.1 | Principal Life Insurance Company | A+ | |||||||||||||||||||||
193 | $ | 2,000,000 | M | 80 | 52.2 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
194 | $ | 10,000,000 | M | 80 | 93.7 | New York Life Insurance Company | AA+ | |||||||||||||||||||||
195 | $ | 5,000,000 | M | 80 | 86.8 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
196 | $ | 10,000,000 | M | 80 | 129.2 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
197 | $ | 2,000,000 | M | 80 | 83.6 | Ohio National Life Assurance Corporation | AA- | |||||||||||||||||||||
198 | $ | 1,000,000 | M | 80 | 83.6 | Ohio National Life Assurance Corporation | AA- | |||||||||||||||||||||
199 | $ | 3,000,000 | F | 80 | 122.1 | West Coast Life Insurance Company | AA- | |||||||||||||||||||||
200 | $ | 7,000,000 | M | 80 | 101.7 | Genworth Life Insurance Company | A- |
Face Amount
|
Gender
|
Age (ALB)(1)
|
LE(2)
|
Carrier
|
S&P
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
201 | $ | 8,000,000 | M | 79 | 96.6 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
202 | $ | 2,000,000 | M | 79 | 38.7 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
203 | $ | 1,000,000 | M | 79 | 69.7 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
204 | $ | 2,000,000 | F | 79 | 105.2 | Pacific Life Insurance Company | A+ | |||||||||||||||||||||
205 | $ | 3,000,000 | M | 79 | 113.7 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
206 | $ | 1,750,000 | M | 79 | 97.6 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
207 | $ | 250,000 | M | 79 | 94.4 | American General Life Insurance Company | A+ | |||||||||||||||||||||
208 | $ | 2,000,000 | F | 79 | 103.5 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
209 | $ | 3,000,000 | M | 79 | 125.9 | Principal Life Insurance Company | A+ | |||||||||||||||||||||
210 | $ | 5,000,000 | M | 79 | 109.1 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
211 | $ | 5,000,000 | M | 79 | 109.1 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
212 | $ | 3,000,000 | M | 78 | 55.4 | Pacific Life Insurance Company | A+ | |||||||||||||||||||||
213 | $ | 3,000,000 | M | 78 | 55.4 | Minnesota Life Insurance Company | A+ | |||||||||||||||||||||
214 | $ | 3,000,000 | M | 78 | 55.4 | Prudential Life Insurance Company | AA- | |||||||||||||||||||||
215 | $ | 3,000,000 | M | 78 | 106.3 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
216 | $ | 5,000,000 | M | 78 | 94.1 | Pacific Life Insurance Company | A+ | |||||||||||||||||||||
217 | $ | 5,000,000 | M | 78 | 94.1 | Pacific Life Insurance Company | A+ | |||||||||||||||||||||
218 | $ | 4,000,000 | M | 78 | 95.3 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
219 | $ | 3,601,500 | M | 78 | 110.6 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
220 | $ | 5,000,000 | M | 78 | 130.3 | Principal Life Insurance Company | A+ | |||||||||||||||||||||
221 | $ | 5,000,000 | M | 78 | 106.8 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
222 | $ | 7,000,000 | M | 78 | 102.4 | Lincoln Benefit Life Company | BBB+ | |||||||||||||||||||||
223 | $ | 476,574 | M | 78 | 87.9 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
224 | $ | 6,000,000 | M | 78 | 140.0 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
225 | $ | 130,000 | M | 78 | 62.7 | Genworth Life Insurance Company | A- | |||||||||||||||||||||
226 | $ | 1,000,000 | M | 78 | 140.9 | Empire General Life Assurance Corporation | AA- | |||||||||||||||||||||
227 | $ | 4,300,000 | F | 78 | 127.3 | American National Insurance Company | A | |||||||||||||||||||||
228 | $ | 6,000,000 | M | 78 | 124.2 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
229 | $ | 750,000 | M | 78 | 85.4 | Lincoln National Life Insurance Company | AA- | |||||||||||||||||||||
230 | $ | 500,000 | M | 78 | 61.2 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
231 | $ | 5,000,000 | M | 77 | 93.6 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
232 | $ | 1,000,000 | M | 77 | 107.1 | Sun Life Assurance Company of Canada (U.S.) | BBB | |||||||||||||||||||||
233 | $ | 5,000,000 | M | 77 | 105.4 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
234 | $ | 1,009,467 | M | 77 | 62.7 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
235 | $ | 4,000,000 | M | 77 | 63.9 | MetLife Investors USA Insurance Company | AA- | |||||||||||||||||||||
236 | $ | 2,500,000 | M | 77 | 104.3 | Massachusetts Mutual Life Insurance Company | AA+ | |||||||||||||||||||||
237 | $ | 2,500,000 | M | 77 | 104.3 | Massachusetts Mutual Life Insurance Company | AA+ | |||||||||||||||||||||
238 | $ | 5,000,000 | M | 77 | 71.3 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
239 | $ | 2,250,000 | M | 77 | 111.0 | Massachusetts Mutual Life Insurance Company | AA+ | |||||||||||||||||||||
240 | $ | 3,750,000 | M | 77 | 72.5 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
241 | $ | 1,000,000 | M | 77 | 127.8 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
242 | $ | 5,000,000 | F | 77 | 134.3 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
243 | $ | 3,000,000 | M | 77 | 112.4 | Principal Life Insurance Company | A+ | |||||||||||||||||||||
244 | $ | 5,000,000 | M | 76 | 136.1 | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||||||||||
245 | $ | 500,000 | M | 76 | 82.3 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
246 | $ | 1,000,000 | M | 76 | 126.3 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
247 | $ | 2,840,000 | M | 76 | 116.1 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
248 | $ | 500,000 | F | 76 | 134.2 | Columbus Life Insurance Company | AA | |||||||||||||||||||||
249 | $ | 750,000 | M | 76 | 19.7 | U.S. Financial Life Insurance Company | A+ | |||||||||||||||||||||
250 | $ | 1,000,000 | F | 76 | 92.2 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
251 | $ | 1,750,000 | M | 76 | 78.1 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
252 | $ | 5,000,000 | M | 76 | 121.2 | Transamerica Life Insurance Company | AA- |
Face Amount
|
Gender
|
Age (ALB)(1)
|
LE(2)
|
Carrier
|
S&P
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
253 | $ | 2,000,000 | F | 76 | 72.0 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
254 | $ | 4,000,000 | M | 75 | 83.9 | Massachusetts Mutual Life Insurance Company | AA+ | |||||||||||||||||||||
255 | $ | 7,000,000 | F | 75 | 142.4 | Pacific Life Insurance Company | A+ | |||||||||||||||||||||
256 | $ | 1,000,000 | M | 75 | 101.2 | Pacific Life Insurance Company | A+ | |||||||||||||||||||||
257 | $ | 490,620 | M | 75 | 104.5 | Ameritas Life Insurance Corporation | A+ | |||||||||||||||||||||
258 | $ | 600,000 | M | 75 | 101.6 | Protective Life Insurance Company | AA- | |||||||||||||||||||||
259 | $ | 5,000,000 | M | 75 | 76.0 | West Coast Life Insurance Company | AA- | |||||||||||||||||||||
260 | $ | 5,000,000 | M | 74 | 169.1 | Prudential Life Insurance Company | AA- | |||||||||||||||||||||
261 | $ | 3,000,000 | M | 74 | 72.0 | Aviva Life Insurance Company | N/A | |||||||||||||||||||||
262 | $ | 8,000,000 | M | 74 | 122.6 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
263 | $ | 2,000,000 | F | 74 | 139.0 | Aviva Life Insurance Company | N/A | |||||||||||||||||||||
264 | $ | 5,000,000 | M | 74 | 46.5 | Lincoln Benefit Life Company | BBB+ | |||||||||||||||||||||
265 | $ | 850,000 | M | 74 | 83.0 | New York Life Insurance Company | AA+ | |||||||||||||||||||||
266 | $ | 200,000 | M | 73 | 87.7 | ING Life Insurance and Annuity Company | A- | |||||||||||||||||||||
267 | $ | 300,000 | M | 73 | 28.4 | Lincoln National Life Insurance Company | AA- | |||||||||||||||||||||
268 | $ | 3,000,000 | F | 73 | 136.3 | General American Life Insurance Company | AA- | |||||||||||||||||||||
269 | $ | 500,000 | M | 72 | 49.6 | Midland National Life Insurance Company | A+ | |||||||||||||||||||||
270 | $ | 3,000,000 | M | 72 | 93.8 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
271 | $ | 1,000,000 | M | 72 | 87.2 | United of Omaha Life Insurance Company | A+ | |||||||||||||||||||||
272 | $ | 2,000,000 | M | 72 | 118.6 | American General Life Insurance Company | A+ | |||||||||||||||||||||
273 | $ | 2,500,000 | M | 71 | 118.2 | American General Life Insurance Company | A+ | |||||||||||||||||||||
274 | $ | 1,167,000 | M | 71 | 42.5 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
275 | $ | 2,000,000 | M | 70 | 124.0 | New York Life Insurance Company | AA+ | |||||||||||||||||||||
276 | $ | 2,000,000 | M | 70 | 124.0 | New York Life Insurance Company | AA+ | |||||||||||||||||||||
277 | $ | 600,000 | M | 70 | 106.9 | AXA Equitable Life Insurance Company | A+ | |||||||||||||||||||||
278 | $ | 1,500,000 | M | 70 | 133.5 | Metropolitan Life Insurance Company | AA- | |||||||||||||||||||||
279 | $ | 3,000,000 | M | 69 | 96.3 | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||||||||||
280 | $ | 500,000 | M | 69 | 114.6 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
281 | $ | 500,000 | M | 69 | 114.6 | North American Company for Life And Health Insurance | A+ | |||||||||||||||||||||
282 | $ | 2,000,000 | M | 67 | 136.9 | Transamerica Life Insurance Company | AA- | |||||||||||||||||||||
283 | $ | 1,000,000 | M | 67 | 136.9 | Genworth Life Insurance Company | A- | |||||||||||||||||||||
284 | $ | 156,538 | F | 66 | 128.6 | New York Life Insurance Company | AA+ | |||||||||||||||||||||
285 | $ | 2,000,000 | M | 66 | 68.0 | MetLife Investors USA Insurance Company | AA- | |||||||||||||||||||||
286 | $ | 2,000,000 | M | 66 | 68.0 | MetLife Investors USA Insurance Company | AA- | |||||||||||||||||||||
$ | 771,939,841 |
(1)
|
The insured’s age is current as of the measurement date. |
(2)
|
The insured’s life expectancy estimate, other than for a small face value insurance policy benefit, is the average of two life expectancy estimates provided by independent third-party medical actuarial underwriting firms actuarially adjusted through the measurement date. |
(2)
|
The insured’s life expectancy estimate, other than for a small face value insurance policy benefit, is the average of at least two life expectancy estimates provided by independent third-party medical actuarial underwriting firms at the time of purchase, actuarially adjusted through the measurement date. This listing includes 176 policies with updated life expectancy estimates and 22 policies the life expectancy estimate of which has been increased by 7.52% over that earlier provided by 21st Services. Numbers in this column represent months. For more information, see disclosure under the caption “ Pricing Life Insurance Policies .” |
Rank
|
Policy Benefits
|
Percentage
of Policy Benefit Amt. |
Insurance Company
|
Ins. Co. S&P
Rating |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1
|
$123,380,000 | 15.98 | % | AXA Equitable Life Insurance Company | A+ | |||||||||||||
2
|
$85,920,000 | 11.13 | % | John Hancock Life Insurance Company (U.S.A) | AA- | |||||||||||||
3
|
$73,920,000 | 9.58 | % | Transamerica Life Insurance Company | AA- | |||||||||||||
4
|
$56,215,000 | 7.28 | % | ING Life Insurance and Annuity Company | A- | |||||||||||||
5
|
$55,769,000 | 7.22 | % | Jefferson-Pilot Life Insurance Company | AA- | |||||||||||||
6
|
$42,735,000 | 5.54 | % | Massachusetts Mutual Life Insurance Company | AA+ | |||||||||||||
7
|
$39,550,000 | 5.12 | % | American General Life Insurance Company | A+ | |||||||||||||
8
|
$30,500,000 | 3.95 | % | Pacific Life Insurance Company | A+ | |||||||||||||
9
|
$28,450,000 | 3.69 | % | West Coast Life Insurance Company | AA- | |||||||||||||
10
|
$26,661,000 | 3.45 | % | Metropolitan Life Insurance Company | AA- |
States Where
We Conduct Business Directly |
States Where
We Conduct Business Through Other Licensed Providers |
|||||
---|---|---|---|---|---|---|
Alabama*
|
Colorado
|
|||||
Arizona
|
Georgia
|
|||||
Arkansas
|
Kentucky
|
|||||
California
|
Nevada
|
|||||
Connecticut
|
New Jersey
|
States Where
We Conduct Business Directly |
States Where
We Conduct Business Through Other Licensed Providers |
|||||
---|---|---|---|---|---|---|
Delaware
|
Oregon
|
|||||
District
of Columbia*
|
Utah
|
|||||
Florida
|
||||||
Indiana
|
||||||
Illinois
|
||||||
Iowa
|
||||||
Kansas
|
||||||
Louisiana
|
||||||
Maine
|
||||||
Maryland
|
||||||
Massachusetts
|
||||||
Michigan*
|
||||||
Minnesota
|
||||||
Mississippi
|
||||||
Missouri*
|
||||||
Nebraska
|
||||||
New
Mexico*
|
||||||
New
York
|
||||||
North
Carolina
|
||||||
Ohio
|
||||||
Oklahoma
|
||||||
Pennsylvania
|
||||||
Rhode
Island
|
||||||
South
Carolina*
|
||||||
South
Dakota*
|
||||||
Tennessee
|
||||||
Texas
|
||||||
Virginia
|
||||||
Washington
|
||||||
Wisconsin
|
||||||
Wyoming*
|
Name
|
Age
|
Positions
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Jon R. Sabes
|
47 |
Chief
Executive Officer and Director
|
||||||||
Paul A. Siegert
|
74 |
Director (Executive Chairman)
|
||||||||
Steven F. Sabes
|
45 |
President, Secretary and Director
|
||||||||
William
Acheson
|
49 |
Chief Financial Officer
|
||||||||
Jon Gangelhoff
|
55 |
Chief
Operating Officer
|
||||||||
Jeffrey L.
McGregor
|
60 |
Director
|
||||||||
Charles H.
Maguire III
|
70 |
Director
|
||||||||
David H. Abramson
|
72 |
Director
|
Name and Principal Position
|
Salary
|
Bonus (1)
|
All Other
Compensation (2) |
Total
|
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jon R. Sabes
|
2013 | $ | 350,000 | $ | 544,581 | $ | 16,905 | $ | 911,486 | |||||||||||||
Chief
Executive Officer
|
2012 | $ | 350,000 | $ | 163,182 | $ | 0 | $ | 513,182 | |||||||||||||
Jon
Gangelhoff
|
2013 | $ | 120,000 | $ | 57,276 | $ | 13,244 | $ | 190,520 | |||||||||||||
Chief
Financial Officer
|
2012 | $ | 120,000 | $ | 28,244 | $ | 0 | $ | 148,244 | |||||||||||||
Paul A.
Siegert
|
2013 | $ | 150,000 | $ | 54,236 | $ | 2,631 | $ | 206,867 | |||||||||||||
President and
Chairman of the Board
|
2012 | $ | 150,000 | $ | 113,967 | $ | 0 | $ | 263,967 | |||||||||||||
Steven F.
Sabes
|
2013 | $ | 150,000 | $ | 426,836 | $ | 11,063 | $ | 587,899 | |||||||||||||
COO and
Secretary
|
2012 | $ | 150,000 | $ | 35,591 | $ | 0 | $ | 185,591 |
(1)
|
In 2013, Messrs. Jon R. Sabes, Steven F. Sabes, and Paul A. Siegert each received a discretionary bonus related to the tax impact of the conversion of the Company from a limited liability company to a corporation. In this regard, Mr. Jon R. Sabes received a discretionary tax-related bonus of $436,700, Mr. Steven F. Sabes received a discretionary tax-related bonus of $380,600, and Mr. Paul A. Siegert received a discretionary tax-related bonus of $8,000. In addition, each named executive received a cash bonus under the Company’s incentive compensation plan. Mr. Jon R. Sabes received a $107,881 cash bonus, Mr. Gangelhoff received a $57,276 cash bonus, Mr. Siegert received a $46,236 cash bonus, and Mr. Steven F. Sabes received a $46,236 cash bonus, under that incentive compensation plan. |
(2)
|
All Other Compensation includes payment of unused and accrued vacation, and premiums paid by the Company that are reported on the named executives’ W-2 forms as a component of gross income. |
Vested
Shares |
Un-Vested
Shares |
Total
Shares |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jon Sabes
|
— | 12,000 | 12,000 | |||||||||||
Steve Sabes
|
50,000 | 5,000 | 55,000 | |||||||||||
Paul Siegert
|
50,000 | 5,000 | 55,000 | |||||||||||
Jon
Gangelhoff
|
100,000 | 54,000 | 154,000 | |||||||||||
|
200,000 | 76,000 | 276,000 |
Fees
Earned or Paid in Cash |
||||||
---|---|---|---|---|---|---|
Director’s Name
|
2013
|
|||||
Paul A.
Siegert (Chairman)
|
$ | 30,000 | ||||
Jon R. Sabes
|
$ | 30,000 | ||||
Steven F.
Sabes
|
$ | 30,000 | ||||
Brian Tyrell
|
$ | 25,000 | ||||
Laurence
Zipkin
|
$ | 25,000 | ||||
Kenneth Fink
|
$ | 25,000 | ||||
David H.
Abramson
|
$ | 11,000 | ||||
Charles H.
Maguire III
|
$ | 8,000 | ||||
Jeffrey L.
McGregor
|
$ | 8,000 |
•
|
each person known by us to be the beneficial owner of more than five percent of our outstanding common stock |
•
|
each of our current directors |
•
|
each our current executive officers and any other persons identified as a “named executive” in the Summary Compensation Table above, and |
•
|
all our current executive officers and directors as a group. |
Percentage of Shares
Beneficially Owned |
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Name and Address
|
Shares
Beneficially Owned |
Prior to
Offering |
After
Offering |
||||||||||||
Jon R. Sabes
(1)
|
4,854,788 | 47.6 | % | ||||||||||||
Steven S.
Sabes (2)
|
4,772,494 | 46.8 | % | ||||||||||||
Paul A.
Siegert (3)
|
450,890 | 4.4 | % | ||||||||||||
Jon
Gangelhoff (4)
|
100,000 | 1.0 | % | * | |||||||||||
Willaim B.
Acheson (5)
|
5,000 | * | * | ||||||||||||
David H.
Abramson (6)
|
15,000 | * | * | ||||||||||||
Jeffrey L.
McGregor (7)
|
10,500 | * | * | ||||||||||||
Charles H.
Maguire III (8)
|
10,500 | * | * | ||||||||||||
All current
directors and officers as a group
|
10,212,172 | 99.8 | % |
*
|
less than one percent. |
(1)
|
Mr. Sabes is our Chief Executive Officer and a director of the Company. Shares reflected in the table include 2,184,552 shares held individually, 978,172 shares held by Opportunity Finance, LLC, a Minnesota limited liability company of which Mr. Sabes is a manager and member, 339,342 shares |
|
held by Jon Sabes 1992 Trust No.1, a trust of which Mr. Sabes is the beneficiary, 337,602 shares held by Jon Sabes 12.30.92 Trust, a trust of which Mr. Sabes is a beneficiary, 483,263 shares held by Jon Sabes1982 Trust, a trust of which Mr. Sabes is a beneficiary, and 327,475 shares held by Jon Sabes 1976 Trust, a trust of which Mr. Sabes is a beneficiary. Also 204,382 shares held by Mr. Sabes’ immediate family members. The trustees of each of the trusts are Robert W. Sabes, Steve F. Sabes and Ross A. Sabes. |
(2)
|
Mr. Sabes is our President, Secretary and a director of the Company. Shares reflected in the table include 1,599,558 shares held individually, 978,172 shares held by Opportunity Finance, LLC, a Minnesota limited liability company of which Mr. Sabes is a manager and member, 1,042,316 shares held by SFS Trust 1982, a trust of which Mr. Sabes is the beneficiary, 701,558 shares held by SFS Trust 1992 Esther, a trust of which Mr. Sabes is a beneficiary, and 400,890 shares held by SFS Trust 1976, a trust of which Mr. Sabes is a beneficiary. The trustees of each of the trusts are Robert W. Sabes, Jon R. Sabes and Ross A. Sabes. The number of shares also include 50,000 of vested stock options granted pursuant to stock option agreement dated September 5, 2013 for 55,000 shares at exercise price of $4.14 vesting over a three-year period. |
(3)
|
Mr. Siegert is a director of the Company (Executive Chairman). Shares reflected in the table include 400,890 shares held individually and 50,000 of vested stock options granted pursuant to stock option agreement dated September 5, 2013 for 55,000 shares at an exercise price of $3.76 and vesting over a three-year period. |
(4)
|
Mr. Gangelhoff is our Chief Operating Officer. Shares reflected in the table include 100,000 of vested stock options granted pursuant to a stock option agreement dated September 5, 2013 for 154,000 shares at an exercise price of $3.76 and vesting over a three-year period. |
(5)
|
Mr. Acheson is our Chief Financial Officer. Shares reflected in the table include 5,000 of vested stock options granted pursuant to a stock option agreement dated May 27, 2014 for 65,000 shares at an exercise price of $3.73 and vesting over a three-year period. |
(6)
|
Mr. Abramson is a director of the Company. Shares reflected in the table include 15,000 of vested stock options granted pursuant to a stock option agreement dated October 28, 2013 for 60,000 shares at an exercise price of $3.76 and vesting quarterly over a three-year period. |
(7)
|
Mr. McGregor is a director of the Company. Shares reflected in the table include 10,500 of vested stock options granted pursuant to a stock option agreement dated November 12, 2013 for 42,000 shares at an exercise price of $3.76 and vesting quarterly over a three-year period. |
(8)
|
Mr. Maguire is a director of the Company. Shares reflected in the table include 10,500 of vested stock options granted pursuant to a stock option agreement dated November 12, 2013 for 42,000 shares at an exercise price of $3.76 and vesting quarterly over a three-year period. |
•
|
any breach of his or her duty of loyalty to us or our stockholders; |
•
|
acts or omissions not in good faith which involve intentional misconduct or a knowing violation of law; |
•
|
the payment of dividends or the redemption or purchase of stock in violation of Delaware law; or |
•
|
any transaction from which the director derived an improper personal benefit. |
•
|
1% of the number of shares of common stock then outstanding, which will equal approximately shares immediately after our initial public offering, or |
•
|
the average weekly trading volume of the common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale. |
Name
|
Shares
|
|||||
---|---|---|---|---|---|---|
MLV &
Co. LLC
|
Per Share
|
Total
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Public
offering price
|
$ | $15,000,000 | ||||||||
Underwriting
discounts and commissions
|
$ | $1,050,000 | ||||||||
Proceeds to
us, before expenses
|
$ | $13,950,000 |
•
|
offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or other securities convertible into or exercisable or exchangeable for shares of common stock; |
•
|
enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of shares of common stock; or |
•
|
make a demand for, or in our case file, a registration statement with the SEC relating to the offering of any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock. |
•
|
short sales; |
•
|
purchases to cover positions created by short sales; and |
•
|
stabilizing transactions. |
Page
|
||||||
---|---|---|---|---|---|---|
F-2
|
||||||
F-4
|
||||||
F-5
|
||||||
F-6
|
||||||
F-7
|
||||||
F-9
|
||||||
F-30
|
||||||
F-31
|
||||||
F-32
|
||||||
F-34
|
Year Ended
|
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
December 31,
2013 |
December 31,
2012 |
||||||||||
REVENUE
|
|||||||||||
Gain on life
settlements, net
|
$ | 29,513,642 | $ | 17,436,743 | |||||||
Gain upon
termination of agreement with Athena Securities Ltd.
|
$ | 3,252,400 | — | ||||||||
Interest and
other income
|
298,732 | 89,055 | |||||||||
TOTAL
REVENUE
|
33,064,774 | 17,525,798 | |||||||||
EXPENSES
|
|||||||||||
Interest
expense
|
20,762,644 | 10,878,627 | |||||||||
Employee
compensation and benefits
|
5,043,848 | 2,903,373 | |||||||||
Legal and
professional fees
|
1,754,209 | 1,076,694 | |||||||||
Other
expenses
|
3,525,261 | 2,486,813 | |||||||||
TOTAL
EXPENSES
|
31,085,962 | 17,345,507 | |||||||||
INCOME BEFORE
INCOME TAXES
|
1,978,812 | 180,291 | |||||||||
INCOME TAX
EXPENSE
|
2,173,767 | 1,193,190 | |||||||||
NET
LOSS
|
(194,955 | ) | (1,012,899 | ) | |||||||
Accretion of
preferred stock to liquidation value
|
(806,624 | ) | (1,578,405 | ) | |||||||
LOSS
ATTRIBUTABLE TO COMMON SHAREHOLDERS
|
$ | (1,001,579 | ) | $ | (2,591,304 | ) | |||||
NET LOSS PER
COMMON SHARE
(BASIC AND DILUTED) |
|||||||||||
Net
loss
|
$ | (0.02 | ) | $ | (0.10 | ) | |||||
Accretion of
preferred stock to liquidation value
|
$ | (0.09 | ) | $ | (0.16 | ) | |||||
Net loss per
share attributable to common shareholders
|
$ | (0.11 | ) | $ | (0.26 | ) | |||||
WEIGHTED
AVERAGE SHARES OUTSTANDING
|
|||||||||||
Basic and
diluted
|
9,517,397 | 9,989,000 |
Common
Shares |
Common
Stock (par) |
Additional
Paid-in Capital |
Accumulated
Deficit |
Total
Equity |
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance,
December 31, 2011
|
9,989,000 | $ | 9,989 | $ | 8,169,303 | $ | (7,230,723 | ) | $ | 948,569 | ||||||||||||
Net loss
|
— | — | — | (1,012,899 | ) | (1,012,899 | ) | |||||||||||||||
Issuance of
warrants to purchase common stock
|
— | — | 380,946 | — | 380,946 | |||||||||||||||||
Accretion of
preferred stock to liquidation value
|
— | — | (1,578,405 | ) | — | (1,578,405 | ) | |||||||||||||||
Balance,
December 31, 2012
|
9,989,000 | 9,989 | 6,971,844 | (8,243,622 | ) | (1,261,789 | ) | |||||||||||||||
Net
loss
|
— | — | — | (194,955 | ) | (194,955 | ) | |||||||||||||||
Repurchase of
common stock
|
(865,000 | ) | (865 | ) | (3,251,535 | ) | — | (3,252,400 | ) | |||||||||||||
Stock-based
compensation
|
— | — | 23,753 | — | 23,753 | |||||||||||||||||
Accretion of
preferred stock to liquidation value
|
— | — | (806,624 | ) | — | (806,624 | ) | |||||||||||||||
Balance,
December 31, 2013
|
9,124,000 | $ | 9,124 | $ | 2,937,438 | $ | (8,438,577 | ) | $ | (5,492,015 | ) |
Year Ended
|
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
December 31,
2013 |
December 31,
2012 |
||||||||||
CASH FLOWS
FROM OPERATING ACTIVITIES
|
|||||||||||
Net loss
|
$ | (194,955 | ) | $ | (1,012,899 | ) | |||||
Adjustments
to reconcile net loss to net cash flows used in operating activities:
|
|||||||||||
Gain on life
settlements
|
(39,337,542 | ) | (27,856,374 | ) | |||||||
Amortization
of deferred financing and issuance costs
|
2,470,390 | 1,908,930 | |||||||||
Deferred
income taxes
|
2,173,767 | 1,193,190 | |||||||||
Convertible,
redeemable preferred stock issued in lieu of cash dividends
|
623,899 | 567,478 | |||||||||
Convertible,
redeemable preferred stock dividends payable
|
255 | 338,695 | |||||||||
Gain upon
termination of agreement with Athena Securities Ltd.
|
(3,252,400 | ) | — | ||||||||
(Increase)
decrease in operating assets:
|
|||||||||||
Due from
related parties
|
8,613 | (6,348 | ) | ||||||||
Death
benefits receivable
|
2,850,000 | (2,850,000 | ) | ||||||||
Other assets
|
(566,418 | ) | (869,165 | ) | |||||||
Increase
(decrease) in operating liabilities:
|
|||||||||||
Accounts
payable
|
369,809 | (257,708 | ) | ||||||||
Interest
payable
|
3,418,432 | 1,744,599 | |||||||||
Other accrued
expenses
|
50,642 | (69,292 | ) | ||||||||
NET CASH
FLOWS USED IN OPERATING ACTIVITIES
|
(31,385,508 | ) | (27,168,894 | ) | |||||||
CASH FLOWS
FROM INVESTING ACTIVITIES
|
|||||||||||
Investment in
life settlements
|
(34,997,500 | ) | (15,067,495 | ) | |||||||
Proceeds from
settlement of life settlements
|
4,563,896 | 1,067,210 | |||||||||
NET CASH
FLOWS USED IN INVESTING ACTIVITIES
|
(30,433,604 | ) | (14,000,285 | ) | |||||||
CASH FLOWS
FROM FINANCING ACTIVITIES
|
|||||||||||
Net proceeds
from revolving credit facility
|
8,000,000 | 11,000,000 | |||||||||
Payments for
redemption of Series I Secured notes payable
|
(8,671,624 | ) | (7,477,197 | ) | |||||||
Proceeds from
issuance of Renewable Secured Debentures
|
85,260,976 | 58,553,280 | |||||||||
Payment of
deferred issuance costs for Renewable Secured Debentures
|
(4,320,542 | ) | (3,024,545 | ) | |||||||
Payments for
redemption of Renewable Secured Debentures
|
(8,143,363 | ) | (112,500 | ) | |||||||
Proceeds from
(uses of) restricted cash
|
(3,739,878 | ) | 2,701,210 | ||||||||
Issuance
(redemption) of convertible, redeemable preferred stock
|
(613,708 | ) | 6,414,273 | ||||||||
Payments of
issuance cost for convertible, redeemable preferred stock
|
— | (1,266,647 | ) | ||||||||
NET CASH
FLOWS PROVIDED BY FINANCING ACTIVITIES
|
67,771,861 | 66,787,874 | |||||||||
NET INCREASE
IN CASH AND CASH EQUIVALENTS
|
5,952,749 | 25,618,695 | |||||||||
CASH AND
CASH EQUIVALENTS
|
|||||||||||
BEGINNING OF
PERIOD
|
27,497,044 | 1,878,349 | |||||||||
END OF PERIOD
|
$ | 33,449,793 | $ | 27,497,044 |
Year Ended
|
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
December 31,
2013 |
December 31,
2012 |
||||||||||
SUPPLEMENTAL
DISCLOSURES OF CASH FLOW INFORMATION
|
|||||||||||
Interest and
preferred dividends paid
|
$ | 13,627,000 | $ | 6,280,000 | |||||||
NON-CASH
INVESTING AND FINANCING ACTIVITIES
|
|||||||||||
Non-cash
conversion of Series I Secured notes
|
$ | 912,000 | $ | 4,220,000 | |||||||
Non-cash
conversion of accrued interest payable on Series I Secured notes
|
$ | — | $ | 6,000 | |||||||
Warrants
issued to purchase common stock
|
$ | — | $ | 381,000 | |||||||
Options
issued to purchase common stock
|
$ | 24,000 | $ | — | |||||||
Accrued
interest payable on Series I Secured notes added to principal
|
$ | 185,000 | $ | 142,000 | |||||||
Accrued
interest payable on Renewable Secured Debentures added to principal
|
$ | 141,000 | $ | 13,000 | |||||||
Unsettled
life settlements included in accounts payable
|
$ | — | $ | 292,000 |
1)
|
Receipt of death notice or verified obituary of insured |
2)
|
Sale of policy and filing of change of ownership forms and receipt of payment |
As of December 31, 2013
|
As of December 31, 2012
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Years Ending December 31,
|
Number of
Contracts |
Estimated
Fair Value |
Face
Value |
Number of
Contracts |
Estimated
Fair Value |
Face
Value |
|||||||||||||||||||||
2014
|
— | $ | — | $ | — | — | $ | — | $ | — | |||||||||||||||||
2015
|
4 | 5,065,000 | 6,750,000 | — | — | — | |||||||||||||||||||||
2016
|
8 | 8,174,000 | 13,750,000 | 2 | 1,163,000 | 2,000,000 | |||||||||||||||||||||
2017
|
25 | 33,345,000 | 63,916,000 | 13 | 11,608,000 | 22,229,000 | |||||||||||||||||||||
2018
|
33 | 37,243,000 | 80,318,000 | 17 | 21,155,000 | 53,439,000 | |||||||||||||||||||||
2019
|
34 | 32,844,000 | 89,295,000 | 31 | 28,252,000 | 75,668,000 | |||||||||||||||||||||
2020
|
34 | 27,741,000 | 75,644,000 | 35 | 26,947,000 | 84,579,000 | |||||||||||||||||||||
Thereafter
|
125 | 90,261,000 | 410,975,000 | 113 | 75,192,000 | 334,331,000 | |||||||||||||||||||||
Totals
|
263 | $ | 234,673,000 | $ | 740,648,000 | 211 | $ | 164,317,000 | $ | 572,246,000 |
2013
|
2012
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Change in
fair value
|
$ | 39,338,000 | $ | 27,856,000 | ||||||
Premiums and
other annual fees
|
(21,860,000 | ) | (16,702,000 | ) | ||||||
Policy
maturities
|
12,036,000 | 6,283,000 | ||||||||
Gain on life
settlements, net
|
$ | 29,514,000 | $ | 17,437,000 |
Years Ending December 31,
|
||||||
---|---|---|---|---|---|---|
2014
|
$ | 22,739,000 | ||||
2015
|
25,056,000 | |||||
2016
|
27,508,000 | |||||
2017
|
30,653,000 | |||||
2018
|
33,509,000 | |||||
|
$ | 139,465,000 |
•
|
Level 1 — Valuations based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. |
•
|
Level 2 — Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. |
•
|
Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement. |
2013
|
2012
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Beginning
balance
|
$ | 164,317,000 | $ | 122,169,000 | ||||||
Purchases
|
35,582,000 | 15,359,000 | ||||||||
Maturities
(acquisition cost)
|
(4,564,000 | ) | (1,067,000 | ) | ||||||
Gross
unrealized gains
|
39,338,000 | 28,055,000 | ||||||||
Gross
unrealized losses
|
— | (199,000 | ) | |||||||
Ending
balance
|
$ | 234,673,000 | $ | 164,317,000 |
As of
December 31, 2013 |
As of
December 31, 2012 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Weighted
average age of insured
|
82.1 | 81.3 | ||||||||
Weighted
average life expectancy, months*
|
87.0 | 91.6 | ||||||||
Average face
amount per policy
|
$ | 2,816,000 | $ | 2,712,064 | ||||||
Discount
rate
|
11.69 | % | 12.08 | % |
*
|
Standard life expectancy as adjusted for insured’s specific circumstances. |
Change in life expectancy
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
plus 8
months |
minus
8 months |
plus 4
months |
minus
4 months |
||||||||||||||||
Investment in
life policies
|
|||||||||||||||||||
December 31,
2013
|
$ | (34,382,000 | ) | $ | 36,152,000 | $ | (17,417,000 | ) | $ | 17,865,000 | |||||||||
December 31,
2012
|
$ | (24,072,000 | ) | $ | 25,268,000 | $ | (12,185,000 | ) | $ | 12,484,000 |
Change in discount rate
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
plus 2%
|
minus 2%
|
plus 1%
|
minus 1%
|
||||||||||||||||
Investment in
life policies
|
|||||||||||||||||||
December 31,
2013
|
$ | (22,944,000 | ) | $ | 27,063,000 | $ | (11,933,000 | ) | $ | 12,959,000 | |||||||||
December 31,
2012
|
$ | (16,811,000 | ) | $ | 19,978,000 | $ | (8,759,000 | ) | $ | 9,547,000 |
Month issued
|
Warrants
issued |
Fair value
per share |
Risk free
rate |
Volatility
|
Term
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
December 2011
|
137,874 | $ | 0.11 | 0.42 | % | 25.25 | % | 3 | years | |||||||||||||
March 2012
|
76,260 | $ | 0.26 | 0.38 | % | 36.20 | % | 3 | years | |||||||||||||
June 2012
|
323,681 | $ | 0.58 | 0.41 | % | 47.36 | % | 3 | years | |||||||||||||
July 2012
|
289,093 | $ | 0.58 | 0.41 | % | 47.36 | % | 3 | years | |||||||||||||
September 2012
|
5,000 | $ | 0.36 | 0.31 | % | 40.49 | % | 3 | years | |||||||||||||
|
831,908 |
•
|
changing its corporate name, offices, and jurisdiction of incorporation |
•
|
changing any deposit accounts or payment instructions to insurers; |
•
|
changing any operating policies and practices such that it would be reasonably likely to adversely affect the collectability of any asset in any material respect; |
•
|
merging or consolidating with, or selling all or substantially all of its assets to, any third party; |
•
|
selling any collateral or creating or permitting to exist any adverse claim upon any collateral; |
•
|
engaging in any other business or activity than that contemplated by the Agreement; |
•
|
incurring or guaranteeing any debt for borrowed money; |
•
|
amending the Company’s certificate of incorporation or bylaws, making any loans or advances to, investments in, or paying any dividends to, any person unless both before and after any such loan, advance, investment or dividend there exists no actual event of default, potential event of default or termination event; |
•
|
removing an independent director on the board of directors except for cause or with the consent of the lender; or |
•
|
making payment on or issuing any subsidiary secured notes or debentures, or amending any agreements respecting such notes or debentures, if an event of default, potential event of default or termination event exists or would arise from any such action. |
Years Ending December 31,
|
||||||
---|---|---|---|---|---|---|
2014
|
$ | 16,111,000 | ||||
2015
|
6,700,000 | |||||
2016
|
2,030,000 | |||||
2017
|
4,085,000 | |||||
2018
|
754,000 | |||||
Thereafter
|
64,000 | |||||
|
$ | 29,744,000 |
Years Ending December 31,
|
||||||
---|---|---|---|---|---|---|
2013
|
$ | 34,258,000 | ||||
2014
|
41,509,000 | |||||
2015
|
29,152,000 | |||||
2016
|
7,667,000 | |||||
2017
|
5,381,000 | |||||
Thereafter
|
16,924,000 | |||||
|
$ | 134,891,000 |
•
|
Up to 33% of the holder’s unredeemed shares one year after issuance: |
•
|
Up to 66% of the holder’s unredeemed shares two years after issuance; and |
•
|
Up to 100% of the holder’s unredeemed shares three years after issuance. |
Income tax provision:
|
2013
|
2012
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Deferred:
|
||||||||||
Federal
|
$ | 1,826,000 | $ | 1,002,000 | ||||||
State
|
348,000 | 191,000 | ||||||||
Total income
tax expense
|
$ | 2,174,000 | $ | 1,193,000 |
2013
|
2012
|
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statutory federal income tax
|
$ | 673,000 | 34.0 | % | $ | 61,000 | 34.0 | % | |||||||||||
State
income taxes, net of federal benefit
|
298,000 | 15.1 | % | 165,000 | 91.2 | % | |||||||||||||
Series
A preferred stock dividends
|
860,000 | 43.4 | % | 757,000 | 420.1 | % | |||||||||||||
Other
permanent differences
|
343,000 | 17.3 | % | 210,000 | 116.5 | % | |||||||||||||
Total
income tax expense
|
$ | 2,174,000 | 109.8 | % | $ | 1,193,000 | 661.8 | % |
2013
|
2012
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Deferred tax
assets:
|
||||||||||
Athena
Securities Group, LTD, advisory services
|
$ | — | $ | 1,455,000 | ||||||
Note
receivable from related party
|
2,023,000 | 2,023,000 | ||||||||
Net operating
loss carryforwards
|
2,596,000 | 1,671,000 | ||||||||
Other assets
|
164,000 | 20,000 | ||||||||
Subtotal
|
4,783,000 | 5,169,000 | ||||||||
Valuation
allowance
|
(2,164,000 | ) | (2,023,000 | ) | ||||||
Net deferred
tax asset
|
2,619,000 | 3,146,000 | ||||||||
Deferred tax
liabilities:
|
||||||||||
Investment in
life settlements
|
(10,294,000 | ) | (8,647,000 | ) | ||||||
Net deferred
tax liability
|
$ | (7,675,000 | ) | $ | (5,501,000 | ) |
Grant Date
|
Exercise
Price |
Shares
|
Vesting
|
Binomial
Value |
Forfeiture
Factor |
Compensation
Expense |
||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9/5/2013 | $ | 3.76 | 335,000 |
Immediate
|
0.18 | 0.8700 | $ | 52,461 | * | |||||||||||||||||
9/5/2013 | $ | 3.76 | 94,333 |
1 year
|
0.18 | 0.8500 | $ | 14,433 | ||||||||||||||||||
9/5/2013 | $ | 3.76 | 94,333 |
2 years
|
0.30 | 0.7225 | $ | 20,447 | ||||||||||||||||||
9/5/2013 | $ | 3.76 | 94,334 |
3 years
|
0.41 | 0.6141 | $ | 23,752 | ||||||||||||||||||
9/30/2013 | $ | 3.76 | 8,000 |
Immediate
|
0.33 | 0.8700 | $ | 2,297 | * | |||||||||||||||||
10/28/2013 | $ | 3.76 | 34,000 |
1 year
|
0.33 | 0.8500 | $ | 3,927 | ||||||||||||||||||
10/28/2013 | $ | 3.76 | 34,000 |
2 years
|
0.46 | 0.7225 | $ | 4,653 | ||||||||||||||||||
10/28/2013 | $ | 3.76 | 34,000 |
3 years
|
0.57 | 0.6141 | $ | 4,901 | ||||||||||||||||||
11/12/2013 | $ | 3.76 | 14,000 |
1 year
|
0.33 | 0.8500 | $ | 9,537 | ||||||||||||||||||
11/12/2013 | $ | 3.76 | 14,000 |
2 years
|
0.46 | 0.7225 | $ | 11,300 | ||||||||||||||||||
11/12/2013 | $ | 3.76 | 14,000 |
3 years
|
0.57 | 0.6141 | $ | 11,901 | ||||||||||||||||||
12/12/2013 | $ | 3.76 | 60,000 |
Immediate
|
0.33 | 0.8700 | $ | 17,226 | * | |||||||||||||||||
830,000 |
*
|
Amounts reflected in current period earnings. |
Vested
|
Un-vested
|
Total
|
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance as of
December 31, 2012
|
— | — | — | |||||||||||
Granted
during the year
|
403,000 | 427,000 | 830,000 | |||||||||||
Exercised
during the year
|
— | — | — | |||||||||||
Forfeited
during the year
|
(27,500 | ) | (28,500 | ) | (56,000 | ) | ||||||||
Expired
during the year
|
— | — | — | |||||||||||
Balance as of
December 31, 2013
|
375,500 | 398,500 | 774,000 |
December 31,
2013 |
December 31,
201 2 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
NET
LOSS
|
$ | (194,955 | ) | $ | (1,012,899 | ) | ||||
Accretion of
preferred stock to liquidation value
|
(806,624 | ) | (1,578,405 | ) | ||||||
LOSS
ATTRIBUTABE TO COMMON SHAREHOLDERS
|
$ | (1,001,579 | ) | $ | (2,591,304 | ) | ||||
Basic and
diluted weighted average shares outstanding
|
9,517,397 | 9,989,000 | ||||||||
NET LOSS PER
COMMON SHARE (BASIC AND DILUTED)
|
||||||||||
Net
loss
|
$ | (0.02 | ) | $ | (0.10 | ) | ||||
Accretion of
value to preferred stock
|
$ | (0.09 | ) | $ | (0.16 | ) | ||||
Net loss
attributable to common shareholders
|
$ | (0.11 | ) | $ | (0.26 | ) |
2014
|
104,000 | |||||
2015
|
70,000 | |||||
Total
|
$ | 174,000 |
For the year ended December 31, 2013
|
Parent
|
Guarantor
Subsidiary |
Non-
Guarantor Subsidiaries |
Eliminations
|
Consolidated
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE
|
||||||||||||||||||||||
Contract
servicing fees
|
$ | — | $ | 3,710,737 | $ | — | $ | (3,710,737 | ) | $ | — | |||||||||||
Gain on life
settlements, net
|
— | — | 29,513,642 | — | 29,513,642 | |||||||||||||||||
Gain upon
termination of agreement with Athena Securities Ltd.
|
$ | 3,252,400 | — | — | — | $ | 3,252,400 | |||||||||||||||
Interest and
other income
|
81,931 | 2,612,420 | 79,767 | (2,475,386 | ) | 298,732 | ||||||||||||||||
TOTAL REVENUE
|
3,334,331 | 6,323,157 | 29,593,409 | (6,186,123 | ) | 33,064,774 | ||||||||||||||||
EXPENSES
|
||||||||||||||||||||||
Origination
and servicing fees
|
— | — | 3,710,737 | (3,710,737 | ) | — | ||||||||||||||||
Interest
expense
|
11,800,718 | 3,684,811 | 5,277,115 | — | 20,762,644 | |||||||||||||||||
Employee
compensation and benefits
|
3,424,383 | 1,619,465 | — | — | 5,043,848 | |||||||||||||||||
Legal and
professional fees
|
1,206,520 | 514,728 | 32,961 | — | 1,754,209 | |||||||||||||||||
Other
expenses
|
2,004,636 | 1,463,084 | 2,532,927 | (2,475,386 | ) | 3,525,261 | ||||||||||||||||
TOTAL
EXPENSES
|
18,436,257 | 7,282,088 | 11,553,740 | (6,186,123 | ) | 31,085,962 | ||||||||||||||||
INCOME (LOSS)
BEFORE EQUITY IN
INCOME OF SUBSIDIARIES |
(15,101,926 | ) | (958,931 | ) | 18,039,669 | — | 1,978,812 | |||||||||||||||
EQUITY IN
INCOME OF SUBSIDIARIES
|
17,080,738 | 18,088,189 | — | (35,168,927 | ) | — | ||||||||||||||||
NET INCOME
BEFORE INCOME TAXES
|
1,978,812 | 17,129,258 | 18,039,669 | (35,168,927 | ) | 1,978,812 | ||||||||||||||||
INCOME TAX
EXPENSE
|
2,173,767 | — | — | — | 2,173,767 | |||||||||||||||||
NET INCOME
(LOSS)
|
(194,955 | ) | 17,129,258 | 18,039,669 | (35,168,927 | ) | (194,955 | ) | ||||||||||||||
Accretion of
preferred stock to liquidation value
|
(806,624 | ) | — | — | — | (806,624 | ) | |||||||||||||||
LOSS
ATTRIBUTABLE TO COMMON SHAREHOLDERS
|
$ | (1,001,579 | ) | $ | 17,129,258 | $ | 18,039,669 | $ | (35,168,927 | ) | $ | (1,001,579 | ) |
For the year ended December 31, 2012
|
Parent
|
Guarantor
Subsidiary |
Non-
Guarantor Subsidiaries |
Eliminations
|
Consolidated
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE
|
||||||||||||||||||||||
Contract
servicing fees
|
$ | — | $ | 2,539,437 | $ | — | $ | (2,539,437 | ) | $ | — | |||||||||||
Gain on life
settlements, net
|
— | — | 17,436,743 | — | 17,436,743 | |||||||||||||||||
Interest and
other income
|
42,668 | 223,311 | 42,747 | (219,671 | ) | 89,055 | ||||||||||||||||
TOTAL REVENUE
|
42,668 | 2,762,748 | 17,479,490 | (2,759,108 | ) | 17,525,798 | ||||||||||||||||
EXPENSES
|
||||||||||||||||||||||
Origination
and servicing fees
|
— | — | 2,539,437 | (2,539,437 | ) | — | ||||||||||||||||
Interest
expense
|
4,311,719 | 4,833,058 | 1,953,521 | (219,671 | ) | 10,878,627 | ||||||||||||||||
Employee
compensation and benefits
|
— | 2,903,373 | — | — | 2,903,373 | |||||||||||||||||
Legal and
professional fees
|
899,588 | 162,323 | 14,783 | — | 1,076,694 | |||||||||||||||||
Other
expenses
|
937,562 | 1,496,752 | 52,499 | — | 2,486,813 | |||||||||||||||||
TOTAL
EXPENSES
|
6,148,869 | 9,395,506 | 4,560,240 | (2,759,108 | ) | 17,345,507 | ||||||||||||||||
INCOME (LOSS)
BEFORE EQUITY IN
INCOME OF SUBSIDIARIES |
(6,106,201 | ) | (6,632,758 | ) | 12,919,250 | — | 180,291 | |||||||||||||||
EQUITY IN
INCOME OF SUBSIDIARIES
|
6,286,492 | 13,035,698 | — | (19,322,190 | ) | — | ||||||||||||||||
NET INCOME
BEFORE INCOME TAXES
|
180,291 | 6,402,940 | 12,919,250 | (19,322,190 | ) | 180,291 | ||||||||||||||||
INCOME TAX
EXPENSE
|
1,193,190 | — | — | — | 1,193,190 | |||||||||||||||||
NET INCOME
(LOSS)
|
(1,012,899 | ) | 6,402,940 | 12,919,250 | (19,322,190 | ) | (1,012,899 | ) | ||||||||||||||
Accretion of
preferred stock to liquidation value
|
(1,578,405 | ) | — | — | — | (1,578,405 | ) | |||||||||||||||
LOSS
ATTRIBUTABLE TO COMMON SHAREHOLDERS
|
$ | (2,591,304 | ) | $ | 6,402,940 | $ | 12,919,250 | $ | (19,322,190 | ) | $ | (2,591,304 | ) |
For the year ended December 31, 2013
|
Parent
|
Guarantor
Subsidiary |
Non-
Guarantor Subsidiaries |
Eliminations
|
Consolidated
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS
FROM OPERATING ACTIVITIES
|
||||||||||||||||||||||
Net income
(loss)
|
$ | (194,955 | ) | $ | 17,129,258 | $ | 18,039,669 | $ | (35,168,927 | ) | $ | (194,955 | ) | |||||||||
Adjustments to
reconcile net income (loss) to cash flows from operating activities:
|
||||||||||||||||||||||
Equity of
subsidiaries
|
(17,080,738 | ) | (18,088,189 | ) | — | 35,168,927 | — | |||||||||||||||
Gain on life
settlements
|
— | — | (39,337,542 | ) | — | (39,337,542 | ) | |||||||||||||||
Amortization
of deferred financing and issuance costs
|
1,908,248 | 823,004 | (260,861 | ) | — | 2,470,391 | ||||||||||||||||
Deferred
income taxes
|
2,173,767 | — | — | — | 2,173,767 | |||||||||||||||||
Preferred
stock issued for dividends
|
623,899 | — | — | — | 623,899 | |||||||||||||||||
Convertible,
redeemable preferred stock dividends payable
|
255 | — | — | — | 255 | |||||||||||||||||
Gain upon
termination of agreement with Athena Securities Ltd.
|
(3,252,400 | ) | — | — | — | (3,252,400 | ) | |||||||||||||||
(Increase)
decrease in operating assets:
|
||||||||||||||||||||||
Due from
related parties
|
— | 8,613 | — | — | 8,613 | |||||||||||||||||
Death
benefits receivable
|
— | — | 2,850,000 | — | 2,850,000 | |||||||||||||||||
Other assets
|
(51,522,808 | ) | (45,077,218 | ) | — | 96,033,606 | (566,420 | ) | ||||||||||||||
Increase
(decrease) in operating liabilities:
|
||||||||||||||||||||||
Accounts
payable
|
160,130 | 1,680 | 208,000 | — | 369,810 | |||||||||||||||||
Interest
payable
|
2,399,975 | 809,540 | 208,918 | — | 3,418,433 | |||||||||||||||||
Other accrued
expenses
|
277,321 | (224,990 | ) | (1,690 | ) | — | 50,641 | |||||||||||||||
NET CASH
FLOWS USED IN OPERATING ACTIVITIES
|
(64,507,306 | ) | (44,618,302 | ) | (18,293,506 | ) | 96,033,606 | (31,385,508 | ) | |||||||||||||
CASH FLOWS
FROM INVESTING ACTIVITIES
|
||||||||||||||||||||||
Investment in
life settlements
|
— | — | (34,997,500 | ) | — | (34,997,500 | ) | |||||||||||||||
Proceeds from
settlement of life settlements
|
— | — | 4,563,896 | — | 4,563,896 | |||||||||||||||||
NET CASH
FLOWS USED IN INVESTING ACTIVITIES
|
— | — | (30,433,604 | ) | — | (30,433,604 | ) | |||||||||||||||
CASH FLOWS
FROM FINANCING ACTIVITIES
|
||||||||||||||||||||||
Net proceeds
from revolving credit facility
|
— | — | 8,000,000 | — | 8,000,000 | |||||||||||||||||
Payments for
redemption of Series I Secured notes payable
|
— | (8,671,624 | ) | — | — | (8,671,624 | ) | |||||||||||||||
Proceeds from
issuance of debentures
|
85,260,976 | — | — | — | 85,260,976 | |||||||||||||||||
Payments for
issuance of debentures
|
(4,320,542 | ) | — | — | — | (4,320,542 | ) | |||||||||||||||
Payments for
redemption of debentures
|
(8,143,363 | ) | — | — | — | (8,143,363 | ) | |||||||||||||||
Proceeds
(payments) from restricted cash
|
— | 328,700 | (4,068,578 | ) | — | (3,739,878 | ) | |||||||||||||||
Issuance of
member capital
|
— | 51,237,918 | 44,795,688 | (96,033,606 | ) | — | ||||||||||||||||
Payments for
redemption of preferred stock
|
(613,708 | ) | — | — | — | (613,708 | ) | |||||||||||||||
NET CASH
FLOWS PROVIDED BY FINANCING ACTIVITIES
|
72,183,363 | 42,894,994 | 48,727,110 | (96,033,606 | ) | 67,771,861 | ||||||||||||||||
NET INCREASE
IN CASH AND CASH EQUIVALENTS
|
7,676,057 | (1,723,308 | ) | — | — | 5,952,749 | ||||||||||||||||
CASH AND
CASH EQUIVALENTS
|
||||||||||||||||||||||
BEGINNING OF
THE YEAR
|
25,035,579 | 2,461,465 | — | — | 27,497,044 | |||||||||||||||||
END OF THE
YEAR
|
$ | 32,711,636 | $ | 738,157 | $ | — | $ | — | $ | 33,449,793 |
For the year ended December 31, 2012
|
Parent
|
Guarantor
Subsidiary |
Non-
Guarantor Subsidiaries |
Eliminations
|
Consolidated
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS
FROM OPERATING ACTIVITIES
|
||||||||||||||||||||||
Net income
(loss)
|
$ | (1,012,899 | ) | $ | 6,402,940 | $ | 12,919,250 | $ | (19,322,190 | ) | $ | (1,012,899 | ) | |||||||||
Adjustments to
reconcile net income (loss) to cash flows from operating activities:
|
||||||||||||||||||||||
Equity of
subsidiaries
|
(6,286,492 | ) | (13,035,698 | ) | — | 19,322,190 | — | |||||||||||||||
Gain on life
settlements
|
— | — | (27,856,374 | ) | — | (27,856,374 | ) | |||||||||||||||
Amortization
of deferred financing and issuance costs
|
506,279 | 1,169,755 | 232,896 | — | 1,908,930 | |||||||||||||||||
Deferred
income taxes
|
1,193,190 | — | — | — | 1,193,190 | |||||||||||||||||
Preferred
stock issued for dividends
|
567,478 | — | — | — | 567,478 | |||||||||||||||||
Convertible,
redeemable preferred stock dividends payable
|
338,695 | — | — | — | 338,695 | |||||||||||||||||
(Increase)
decrease in operating assets:
|
||||||||||||||||||||||
Due from
related parties
|
— | (6,348 | ) | — | — | (6,348 | ) | |||||||||||||||
Death
benefits receivable
|
— | — | (2,850,000 | ) | — | (2,850,000 | ) | |||||||||||||||
Other
assets
|
(33,137,100 | ) | (22,587,090 | ) | (772,090 | ) | 55,627,115 | (869,165 | ) | |||||||||||||
Increase
(decrease) in operating liabilities:
|
||||||||||||||||||||||
Accounts
payable
|
(306,373 | ) | 48,665 | — | — | (257,708 | ) | |||||||||||||||
Interest
payable
|
918,374 | 806,058 | 20,167 | — | 1,744,599 | |||||||||||||||||
Other accrued
expenses
|
(55,890 | ) | (16,352 | ) | 2,950 | — | (69,292 | ) | ||||||||||||||
NET CASH
FLOWS USED IN OPERATING ACTIVITIES
|
(37,274,738 | ) | (27,218,070 | ) | (18,303,201 | ) | 55,627,115 | (27,168,894 | ) | |||||||||||||
CASH FLOWS
FROM INVESTING ACTIVITIES
|
||||||||||||||||||||||
Investment in
life settlements
|
— | — | (15,067,495 | ) | — | (15,067,495 | ) | |||||||||||||||
Proceeds from
settlement of life settlements
|
— | — | 1,067,210 | — | 1,067,210 | |||||||||||||||||
NET CASH
FLOWS USED IN INVESTING ACTIVITIES
|
— | — | (14,000,285 | ) | — | (14,000,285 | ) | |||||||||||||||
CASH FLOWS
FROM FINANCING ACTIVITIES
|
||||||||||||||||||||||
Net proceeds
from revolving credit facility
|
— | — | 11,000,000 | — | 11,000,000 | |||||||||||||||||
Payments for
redemption of Series I Secured notes payable
|
— | (7,477,197 | ) | — | — | (7,477,197 | ) | |||||||||||||||
Proceeds from
issuance of debentures
|
58,553,280 | — | — | — | 58,553,280 | |||||||||||||||||
Payments for
issuance of debentures
|
(3,024,545 | ) | — | — | — | (3,024,545 | ) | |||||||||||||||
Payments for
redemption of debentures
|
(112,500 | ) | — | — | — | (112,500 | ) | |||||||||||||||
Proceeds
(payments) from restricted cash
|
— | (926,473 | ) | 3,627,683 | — | 2,701,210 | ||||||||||||||||
Issuance of
member capital
|
— | 37,951,312 | 17,675,803 | (55,627,115 | ) | — | ||||||||||||||||
Issuance of
preferred stock
|
6,414,273 | — | — | — | 6,414,273 | |||||||||||||||||
Payments for
issuance of preferred stock
|
(1,266,647 | ) | — | — | — | (1,266,647 | ) | |||||||||||||||
NET CASH
FLOWS PROVIDED BY FINANCING ACTIVITIES
|
60,563,861 | 29,547,642 | 32,303,486 | (55,627,115 | ) | 66,787,874 | ||||||||||||||||
NET INCREASE
IN CASH AND CASH EQUIVALENTS
|
23,289,123 | 2,329,572 | — | — | 25,618,695 | |||||||||||||||||
CASH AND
CASH EQUIVALENTS
|
||||||||||||||||||||||
BEGINNING OF
THE YEAR
|
1,746,456 | 131,893 | — | — | 1,878,349 | |||||||||||||||||
END OF THE
YEAR
|
$ | 25,035,579 | $ | 2,461,465 | $ | — | $ | — | $ | 27,497,044 |
December 31,
2013 |
December 31,
2012 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
%
|
%
|
|||||||||
Life
insurance company
|
||||||||||
Company A
|
16.58 | 16.96 | ||||||||
Company B
|
11.34 | 13.80 | ||||||||
Company C
|
* | 11.36 |
*
|
percentage does not exceed 10% of the total face value. |
December 31,
2013 |
December 31,
2012 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
%
|
%
|
|||||||||
State of
residence
|
||||||||||
California
|
28.14 | 28.44 | ||||||||
Florida
|
15.59 | 13.27 | ||||||||
New York
|
10.65 | 11.85 |
March 31,
2014 (unaudited) |
December 31,
2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
ASSETS
|
||||||||||
Cash and cash
equivalents
|
$ | 28,083,299 | $ | 33,449,793 | ||||||
Restricted
cash
|
2,853,763 | 5,832,970 | ||||||||
Investment in
life settlements, at fair value
|
254,503,535 | 234,672,794 | ||||||||
Other assets
|
2,136,666 | 1,424,919 | ||||||||
TOTAL
ASSETS
|
$ | 287,577,263 | $ | 275,380,476 | ||||||
LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)
|
||||||||||
LIABILITIES
|
||||||||||
Revolving
credit facility
|
$ | 79,000,000 | $ | 79,000,000 | ||||||
Series I
Secured notes payable
|
28,602,238 | 29,275,202 | ||||||||
Renewable
Secured Debentures
|
145,989,431 | 131,646,062 | ||||||||
Interest
payable
|
8,399,192 | 7,209,408 | ||||||||
Accounts
payable and accrued expenses
|
1,293,139 | 1,343,952 | ||||||||
Deferred
taxes, net
|
6,720,316 | 7,675,174 | ||||||||
TOTAL
LIABILITIES
|
270,004,316 | 256,149,798 | ||||||||
CONVERTIBLE,
REDEEMABLE PREFERRED STOCK
(par value $0.001; shares authorized 40,000,000; shares issued and outstanding 3,478,219 and 3,394,916; liquidation preference of $26,087,000 and $25,462,000, respectively) |
25,036,056 | 24,722,693 | ||||||||
STOCKHOLDERS’ EQUITY (DEFICIT)
|
||||||||||
Common stock
(par value $0.001: shares authorized 210,000,000; shares issued and outstanding is 9,124,000 on both March 31, 2014 and December 31, 2013)
|
9,124 | 9,124 | ||||||||
Additional
paid-in capital
|
2,867,514 | 2,937,438 | ||||||||
Accumulated
deficit
|
(10,339,747 | ) | (8,438,577 | ) | ||||||
TOTAL
STOCKHOLDERS’ EQUITY (DEFICIT)
|
(7,463,109 | ) | (5,492,015 | ) | ||||||
TOTAL
LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)
|
$ | 287,577,263 | $ | 275,380,476 |
Three Months Ended
|
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
March 31,
2014 |
March 31,
2013 |
||||||||||
REVENUE
|
|||||||||||
Gain on life
settlements, net
|
$ | 5,516,205 | $ | 8,340,356 | |||||||
Interest and
other income
|
7,367 | 167,670 | |||||||||
TOTAL REVENUE
|
5,523,572 | 8,508,026 | |||||||||
EXPENSES
|
|||||||||||
Employee
compensation and benefits
|
968,746 | 1,937,420 | |||||||||
Legal and
professional fees
|
325,298 | 437,290 | |||||||||
Interest
expense
|
6,326,548 | 4,467,215 | |||||||||
Other
expenses
|
759,008 | 1,033,144 | |||||||||
TOTAL
EXPENSES
|
8,379,600 | 7,875,069 | |||||||||
INCOME (LOSS)
BEFORE INCOME TAXES
|
(2,856,028 | ) | 632,957 | ||||||||
INCOME TAX
EXPENSE (BENEFIT)
|
(954,858 | ) | 565,823 | ||||||||
NET INCOME
(LOSS)
|
(1,901,170 | ) | 67,134 | ||||||||
Accretion of
preferred stock to liquidation value
|
(125,714 | ) | (257,763 | ) | |||||||
LOSS
ATTRIBUTABLE TO COMMON SHAREHOLDERS
|
$ | (2,026,884 | ) | $ | (190,629 | ) | |||||
NET INCOME
(LOSS) PER COMMON SHARE
(BASIC AND DILUTED) |
|||||||||||
Net income
(loss)
|
$ | (0.21 | ) | $ | 0.01 | ||||||
Accretion of
preferred stock to liquidation value
|
(0.01 | ) | (0.03 | ) | |||||||
Net loss per
share attributable to common shareholders
|
$ | (0.22 | ) | $ | (0.02 | ) | |||||
WEIGHTED
AVERAGE SHARES OUTSTANDING
|
|||||||||||
Basic and
diluted
|
9,124,000 | 9,989,000 |
Three Months Ended
|
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
March 31,
2014 |
March 31,
2013 |
||||||||||
CASH FLOWS
FROM OPERATING ACTIVITIES
|
|||||||||||
Net income
(loss)
|
$ | (1,901,170 | ) | $ | 67,134 | ||||||
Adjustments
to reconcile net income (loss) to net cash flows from operating activities:
|
|||||||||||
Life
settlements — change in fair value
|
(11,358,913 | ) | (11,494,725 | ) | |||||||
Amortization
of deferred financing and issuance costs
|
353,657 | 1,093,747 | |||||||||
Deferred
income taxes
|
(954,858 | ) | 563,874 | ||||||||
Convertible,
redeemable preferred stock dividends payable
|
192,340 | 83,702 | |||||||||
(Increase)
decrease in operating assets:
|
|||||||||||
Other assets
|
(251,846 | ) | 551,174 | ||||||||
Increase in
operating liabilities:
|
|||||||||||
Accounts
payable and other accrued expenses
|
1,277,826 | 1,290,756 | |||||||||
NET CASH
FLOWS USED IN OPERATING ACTIVITIES
|
(12,642,964 | ) | (7,844,338 | ) | |||||||
CASH FLOWS
FROM INVESTING ACTIVITIES
|
|||||||||||
Investment in
life settlements
|
(8,271,203 | ) | (9,913,049 | ) | |||||||
Proceeds from
settlement of life settlements
|
— | 1,490,000 | |||||||||
NET CASH
FLOWS USED IN INVESTING ACTIVITIES
|
(8,271,203 | ) | (8,423,049 | ) | |||||||
CASH FLOWS
FROM FINANCING ACTIVITIES
|
|||||||||||
Net proceeds
from revolving credit facility
|
— | 8,000,000 | |||||||||
Payments for
redemption of Series I Secured notes payable
|
(868,303 | ) | (1,507,824 | ) | |||||||
Proceeds from
issuance of Renewable Secured Debentures
|
18,365,657 | 23,850,794 | |||||||||
Payments for
issuance costs and redemption of Renewable Secured Debentures
|
(4,928,888 | ) | (2,303,268 | ) | |||||||
Proceeds
(payments) from restricted cash
|
2,979,207 | (4,531,108 | ) | ||||||||
Issuance of
preferred stock
|
— | (186,669 | ) | ||||||||
NET CASH
FLOWS PROVIDED BY FINANCING ACTIVITIES
|
15,547,673 | 23,321,925 | |||||||||
NET INCREASE
(DECREASE) IN CASH AND CASH EQUIVALENTS
|
(5,366,494 | ) | 7,054,538 | ||||||||
CASH AND
CASH EQUIVALENTS
|
|||||||||||
BEGINNING OF
PERIOD
|
33,449,793 | 27,497,044 | |||||||||
END OF
PERIOD
|
$ | 28,083,299 | $ | 34,551,582 |
Three Months Ended
|
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
March 31,
2014 |
March 31,
2013 |
||||||||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
|
|||||||||||
Interest and
preferred dividends paid
|
$ | 4,250,000 | $ | 3,298,000 | |||||||
NON-CASH
INVESTING AND FINANCING ACTIVITIES
|
|||||||||||
Series I
Secured notes:
|
|||||||||||
Accrued
interest and commissions payable added to principal
|
$ | 65,000 | $ | 61,000 | |||||||
Renewable
Secured Debentures:
|
|||||||||||
Accrued
interest and commissions payable added to principal
|
$ | 119,000 | 41,000 | ||||||||
Convertible,
redeemable preferred stock:
|
|||||||||||
Accretion of
convertible, redeemable preferred stock to redemption value
|
$ | 126,000 | $ | 258,000 | |||||||
Conversion of
dividends payable
|
$ | 188,000 | $ | 84,000 |
1)
|
Receipt of death notice or verified obituary of insured |
2)
|
Sale of policy and filing of change of ownership forms and receipt of payment |
As of March 31, 2014
|
As of December 31, 2013
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Years Ending December 31,
|
Number of
Contracts |
Estimated
Fair Value |
Face Value
|
Number of
Contracts |
Estimated
Fair Value |
Face Value
|
|||||||||||||||||||||
2014
|
— | $ | — | $ | — | — | $ | — | $ | — | |||||||||||||||||
2015
|
4 | 5,238,000 | 6,750,000 | 4 | 5,065,000 | 6,750,000 | |||||||||||||||||||||
2016
|
11 | 10,610,000 | 16,800,000 | 8 | 8,174,000 | 13,750,000 | |||||||||||||||||||||
2017
|
29 | 32,186,000 | 59,916,000 | 25 | 33,345,000 | 63,916,000 | |||||||||||||||||||||
2018
|
30 | 34,573,000 | 71,017,000 | 33 | 37,243,000 | 80,318,000 | |||||||||||||||||||||
2019
|
41 | 43,654,000 | 113,795,000 | 34 | 32,844,000 | 89,295,000 | |||||||||||||||||||||
2020
|
37 | 30,497,000 | 81,014,000 | 34 | 27,741,000 | 75,644,000 | |||||||||||||||||||||
Thereafter
|
134 | 97,746,000 | 422,648,000 | 125 | 90,261,000 | 410,975,000 | |||||||||||||||||||||
Totals
|
286 | $ | 254,504,000 | $ | 771,940,000 | 263 | $ | 234,673,000 | $ | 740,648,000 |
Three Months Ended:
|
March 31,
2014 |
March 31,
2013 |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Change in
fair value
|
$ | 11,359,000 | $ | 11,495,000 | ||||||
Premiums and
other annual fees
|
(5,843,000 | ) | (5,665,000 | ) | ||||||
Policy
maturities
|
— | 2,510,000 | ||||||||
Gain on life
settlements, net
|
$ | 5,516,000 | $ | 8,340,000 |
Years Ending
December 31,
|
||||||
Nine months
ending December 31, 2014
|
$ | 17,882,000 | ||||
2015
|
26,078,000 | |||||
2016
|
28,550,000 | |||||
2017
|
32,109,000 | |||||
2018
|
35,155,000 | |||||
|
$ | 139,774,000 |
•
|
Level 1 — Valuations based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. |
•
|
Level 2 — Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. |
•
|
Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement. |
2014
|
2013
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Beginning
balance
|
$ | 234,673,000 | $ | 164,317,000 | ||||||
Purchases
|
8,472,000 | 10,698,000 | ||||||||
Maturities
(acquisition cost basis)
|
— | (1,490,000 | ) | |||||||
Gross
unrealized gains
|
11,359,000 | 11,616,000 | ||||||||
Gross
unrealized losses
|
— | (121,000 | ) | |||||||
Ending
balance
|
$ | 254,504,000 | $ | 185,020,000 |
As of
March 31, 2014 |
As of
December 31, 2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Weighted
average age of insured
|
82.3 | 82.1 | ||||||||
Weighted
average life expectancy, months*
|
84.3 | 87.0 | ||||||||
Average face
amount per policy
|
$ | 2,699,000 | $ | 2,816,000 | ||||||
Discount
rate
|
11.69 | % | 11.69 | % |
*
|
Standard life expectancy as adjusted for insured’s specific circumstances. |
Changes in fair value of life insurance policies
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Change in life expectancy estimates
|
plus 8
months |
minus
8 months |
plus
4 months |
minus
4 months |
|||||||||||||||
March 31,
2014
|
$ | (36,833,000 | ) | $ | 38,756,000 | $ | (18,658,000 | ) | $ | 19,145,000 | |||||||||
December 31,
2013
|
$ | (34,382,000 | ) | $ | 36,152,000 | $ | (17,417,000 | ) | $ | 17,865,000 |
Change in discount rate
|
plus 2%
|
minus 2%
|
plus 1%
|
minus 1%
|
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
March 31,
2014
|
$ | (23,949,000 | ) | $ | 28,161,000 | $ | (12,446,000 | ) | $ | 13,496,000 | ||||||||
December 31,
2013
|
$ | (22,944,000 | ) | $ | 27,063,000 | $ | (11,933,000 | ) | $ | 12,959,000 |
Month issued
|
Warrants
issued |
Fair value
per share |
Risk
free rate |
Volatility
|
Term
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
December 2011
|
137,874 | $ | 0.11 | 0.42 | % | 25.25 | % | 3 | years | |||||||||||||
March
2012
|
76,260 | $ | 0.26 | 0.38 | % | 36.20 | % | 3 | years | |||||||||||||
June
2012
|
323,681 | $ | 0.58 | 0.41 | % | 47.36 | % | 3 | years | |||||||||||||
July
2012
|
289,093 | $ | 0.58 | 0.41 | % | 47.36 | % | 3 | years | |||||||||||||
September 2012
|
5,000 | $ | 0.36 | 0.31 | % | 40.49 | % | 3 | years | |||||||||||||
|
831,908 |
•
|
changing its corporate name, offices, and jurisdiction of incorporation |
•
|
changing any deposit accounts or payment instructions to insurers; |
•
|
changing any operating policies and practices such that it would be reasonably likely to adversely affect the collectability of any asset in any material respect; |
•
|
merging or consolidating with, or selling all or substantially all of its assets to, any third party; |
•
|
selling any collateral or creating or permitting to exist any adverse claim upon any collateral; |
•
|
engaging in any other business or activity than that contemplated by the Agreement; |
•
|
incurring or guaranteeing any debt for borrowed money; |
•
|
amending the Company’s certificate of incorporation or bylaws, making any loans or advances to, investments in, or paying any dividends to, any person unless both before and after any such loan, advance, investment or dividend there exists no actual event of default, potential event of default or termination event; |
•
|
removing an independent director on the board of directors except for cause or with the consent of the lender; or |
•
|
making payment on or issuing any subsidiary secured notes or debentures, or amending any agreements respecting such notes or debentures, if an event of default, potential event of default or termination event exists or would arise from any such action. |
Years Ending
December 31,
|
||||||
Nine months
ending December 31, 2014
|
$ | 8,323,000 | ||||
2015
|
8,638,000 | |||||
2016
|
7,193,000 | |||||
2017
|
4,252,000 | |||||
2018
|
754,000 | |||||
Thereafter
|
64,000 | |||||
|
$ | 29,224,000 |
Years Ending
December 31,
|
||||||
Nine months
ending December 31, 2014
|
$ | 31,109,000 | ||||
2015
|
44,587,000 | |||||
2016
|
34,623,000 | |||||
2017
|
13,094,000 | |||||
2018
|
6,779,000 | |||||
Thereafter
|
18,873,000 | |||||
|
$ | 149,065,000 |
•
|
Up to 33% of the holder’s unredeemed shares one year after issuance: |
•
|
Up to 66% of the holder’s unredeemed shares two years after issuance; and |
•
|
Up to 100% of the holder’s unredeemed shares three years after issuance. |
Grant Date
|
Exercise
Price |
Shares
|
Vesting
|
Binomial
Value |
Forfeiture
Factor |
Compensation
Expense |
||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9/5/2013 | $ | 3.76 | 285,000 |
Immediate
|
0.18 | 0.8700 | $ | 44,631 | ||||||||||||||||||
9/5/2013 | $ | 4.14 | 50,000 |
Immediate
|
0.18 | 0.8700 | $ | 7,830 | ||||||||||||||||||
9/5/2013 | $ | 3.76 | 88,677 |
1 year
|
0.18 | 0.8500 | $ | 13,568 | ||||||||||||||||||
9/5/2013 | $ | 4.14 | 5,667 |
1 year
|
0.18 | 0.8500 | $ | 867 | ||||||||||||||||||
9/5/2013 | $ | 3.76 | 88,666 |
2 years
|
0.30 | 0.7225 | $ | 19,218 | ||||||||||||||||||
9/5/2013 | $ | 4.14 | 5,667 |
2 years
|
0.30 | 0.7225 | $ | 1,228 | ||||||||||||||||||
9/5/2013 | $ | 3.76 | 88,657 |
3 years
|
0.41 | 0.6141 | $ | 22,323 | ||||||||||||||||||
9/5/2013 | $ | 4.14 | 5,666 |
3 years
|
0.41 | 0.6141 | $ | 1,427 | ||||||||||||||||||
9/30/2013 | $ | 3.76 | 8,000 |
Immediate
|
0.33 | 0.8700 | $ | 2,297 | ||||||||||||||||||
10/28/2013 | $ | 3.76 | 14,000 |
1 year
|
0.33 | 0.8500 | $ | 3,927 | ||||||||||||||||||
10/28/2013 | $ | 3.76 | 14,000 |
2 years
|
0.46 | 0.7225 | $ | 4,653 | ||||||||||||||||||
10/28/2013 | $ | 3.76 | 14,000 |
3 years
|
0.57 | 0.6141 | $ | 4,901 | ||||||||||||||||||
11/18/2013 | $ | 3.76 | 8,334 |
1 year
|
0.33 | 0.8500 | $ | 2,338 | ||||||||||||||||||
11/18/2013 | $ | 3.76 | 8,333 |
2 years
|
0.46 | 0.7225 | $ | 2,769 | ||||||||||||||||||
11/18/2013 | $ | 3.76 | 8,333 |
3 years
|
0.57 | 0.6141 | $ | 2,917 | ||||||||||||||||||
12/12/2013 | $ | 3.76 | 60,000 |
Immediate
|
0.33 | 0.8700 | $ | 17,226 | ||||||||||||||||||
12/12/2013 | $ | 3.76 | 34,000 |
1 year
|
0.33 | 0.8500 | $ | 9,537 | ||||||||||||||||||
12/12/2013 | $ | 3.76 | 34,000 |
2 years
|
0.46 | 0.7225 | $ | 11,300 | ||||||||||||||||||
12/12/2013 | $ | 3.76 | 34,000 |
3 years
|
0.57 | 0.6141 | $ | 11,901 | ||||||||||||||||||
855,000 |
Vested
|
Un-vested
|
Total
|
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance as of
December 31, 2013
|
375,500 | 423,500 | 799,000 | |||||||||||
Granted
during the year
|
— | — | — | |||||||||||
Exercised
during the year
|
— | — | — | |||||||||||
Forfeited
during the year
|
(20,000 | ) | (32,500 | ) | (52,500 | ) | ||||||||
Expired
during the year
|
— | — | — | |||||||||||
Balance as of
March 31, 2014
|
355,500 | 391,000 | 746,500 |
Nine months
ending December 31, 2014
|
78,000 | |||||
2015
|
70,000 | |||||
Total
|
$ | 148,000 |
For the three months ended March 31, 2014
|
Parent
|
Guarantor
Subsidiary |
Non-Guarantor
Subsidiaries |
Eliminations
|
Consolidated
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE
|
||||||||||||||||||||||
Contract
servicing fees
|
$ | — | $ | 966,056 | $ | — | $ | (966,056 | ) | $ | — | |||||||||||
Gain on life
settlements, net
|
— | — | 5,516,205 | — | 5,516,205 | |||||||||||||||||
Interest and
other income
|
6,929 | 169,615 | 44 | (169,221 | ) | 7,367 | ||||||||||||||||
TOTAL
REVENUE
|
6,929 | 1,135,671 | 5,516,249 | (1,135,277 | ) | 5,523,572 | ||||||||||||||||
EXPENSES
|
||||||||||||||||||||||
Origination
and servicing fees
|
— | — | 966,056 | (966,056 | ) | — | ||||||||||||||||
Employee
compensation and benefits
|
590,584 | 378,162 | — | — | 968,746 | |||||||||||||||||
Legal and
professional fees
|
266,159 | 59,139 | — | — | 325,298 | |||||||||||||||||
Interest
expense
|
4,216,528 | 778,567 | 1,331,453 | — | 6,326,548 | |||||||||||||||||
Other
expenses
|
421,243 | 325,255 | 181,731 | (169,221 | ) | 759,008 | ||||||||||||||||
TOTAL
EXPENSES
|
5,494,514 | 1,541,123 | 2,479,240 | (1,135,277 | ) | 8,379,600 | ||||||||||||||||
INCOME (LOSS)
BEFORE EQUITY IN INCOME OF SUBSIDIARIES
|
(5,487,585 | ) | (405,452 | ) | 3,037,009 | — | (2,856,028 | ) | ||||||||||||||
EQUITY IN
INCOME OF SUBSIDIARY
|
2,631,557 | 3,037,009 | — | (5,668,566 | ) | — | ||||||||||||||||
NET INCOME
(LOSS) BEFORE INCOME TAXES
|
(2,856,028 | ) | 2,631,557 | 3,037,009 | (5,668,566 | ) | (2,856,028 | ) | ||||||||||||||
INCOME TAX
BENEFIT
|
(954,858 | ) | — | — | — | (954,858 | ) | |||||||||||||||
NET INCOME
(LOSS)
|
$ | (1,901,170 | ) | $ | 2,631,557 | $ | 3,037,009 | $ | (5,668,566 | ) | $ | (1,901,170 | ) |
For the three months ended March 31, 2013
|
Parent
|
Guarantor
Subsidiary |
Non-Guarantor
Subsidiaries |
Eliminations
|
Consolidated
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE
|
||||||||||||||||||||||
Contract servicing fees
|
$ | — | $ | 1,278,102 | $ | — | $ | (1,278,102 | ) | $ | — | |||||||||||
Gain
on life settlements, net
|
— | — | 8,340,356 | — | 8,340,356 | |||||||||||||||||
Interest and other income
|
8,091 | 136,569 | 23,010 | — | 167,670 | |||||||||||||||||
TOTAL
REVENUE
|
8,091 | 1,414,671 | 8,363,366 | 8,508,026 | ||||||||||||||||||
EXPENSES
|
||||||||||||||||||||||
Origination and servicing fees
|
— | — | 1,278,102 | (1,278,102 | ) | — | ||||||||||||||||
Employee compensation and benefits
|
1,546,702 | 390,718 | — | — | 1,937,420 | |||||||||||||||||
Legal
and professional fees
|
399,523 | 37,767 | — | — | 437,290 | |||||||||||||||||
Interest expense
|
2,321,169 | 907,175 | 1,238,871 | — | 4,467,215 | |||||||||||||||||
Other
expenses
|
634,155 | 386,490 | 12,499 | — | 1,033,144 | |||||||||||||||||
TOTAL
EXPENSES
|
4,901,549 | 1,722,150 | 2,529,472 | (1,278,102 | ) | 7,875,069 | ||||||||||||||||
INCOME
(LOSS) BEFORE EQUITY IN INCOME OF SUBSIDIARIES
|
(4,893,458 | ) | (307,479 | ) | 5,883,894 | — | 632,957 | |||||||||||||||
EQUITY
IN INCOME OF SUBSIDIARY
|
5,526,115 | 5,882,414 | — | (11,408,529 | ) | — | ||||||||||||||||
NET
INCOME BEFORE INCOME TAXES
|
632,657 | 5,574,935 | 5,833,894 | (11,408,529 | ) | 632,957 | ||||||||||||||||
INCOME
TAX EXPENSE
|
565,523 | 300 | — | — | 565,823 | |||||||||||||||||
NET
INCOME
|
$ | 67,134 | $ | 5,574,635 | $ | 5,833,894 | $ | (11,408,529 | ) | $ | 67,134 |
For the three months ended March 31, 2014
|
Parent
|
Guarantor
Sub sidiary |
Non-
Guarantor Sub sidiaries |
Eliminations
|
Consolidated
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS
FROM OPERATING ACTIVITIES
|
||||||||||||||||||||||
Net income
(loss)
|
$ | (1,901,170 | ) | $ | 2,631,557 | $ | 3,037,009 | $ | (5,668,566 | ) | $ | (1,901,170 | ) | |||||||||
Adjustments to
reconcile net loss to cash:
|
||||||||||||||||||||||
(Equity) loss
of subsidiaries
|
(2,631,557 | ) | (3,037,009 | ) | — | 5,668,566 | — | |||||||||||||||
Life
settlements — change in fair value
|
— | — | (11,358,913 | ) | — | (11,358,913 | ) | |||||||||||||||
Amortization
of deferred financing and issuance costs
|
847,236 | 166,946 | (660,525 | ) | — | 353,657 | ||||||||||||||||
Deferred
income taxes
|
(954,858 | ) | — | — | — | (954,858 | ) | |||||||||||||||
Preferred
stock issued for dividends
|
192,340 | — | — | — | 192,340 | |||||||||||||||||
(Increase) in
operating assets:
|
||||||||||||||||||||||
Other
assets
|
(15,947,713 | ) | (15,248,357 | ) | — | 30,944,224 | (251,846 | ) | ||||||||||||||
Increase in
operating liabilities:
|
||||||||||||||||||||||
Accounts
payable and other accrued expenses
|
713,785 | 229,443 | 334,598 | — | 1,277,826 | |||||||||||||||||
NET CASH
FLOWS USED IN OPERATING ACTIVITIES
|
(19,681,937 | ) | (15,257,420 | ) | (8,647,831 | ) | 30,944,224 | (12,642,964 | ) | |||||||||||||
CASH FLOWS
FROM INVESTING ACTIVITIES
|
||||||||||||||||||||||
Investment in
life settlements
|
— | — | (8,271,203 | ) | — | (8,271,203 | ) | |||||||||||||||
NET CASH
FLOWS USED IN INVESTING ACTIVITIES
|
— | — | (8,271,203 | ) | — | (8,271,203 | ) | |||||||||||||||
CASH FLOWS
FROM FINANCING ACTIVITIES
|
||||||||||||||||||||||
Payments for
redemption of Series I Secured notes payable
|
— | (868,303 | ) | — | — | (868,303 | ) | |||||||||||||||
Proceeds from
issuance of debentures
|
18,365,657 | — | — | — | 18,365,657 | |||||||||||||||||
Payments for
issuance costs and redemption of Renewable Secured Debentures
|
(4,928,888 | ) | — | — | — | (4,928,888 | ) | |||||||||||||||
Proceeds from
restricted cash
|
— | 1,070,000 | 1,909,207 | — | 2,979,207 | |||||||||||||||||
Issuance of
member capital
|
— | 15,934,397 | 15,009,827 | (30,944,224 | ) | — | ||||||||||||||||
NET CASH
FLOWS PROVIDED BY FINANCING ACTIVITIES
|
13,436,769 | 16,136,094 | 16,919,034 | (30,944,224 | ) | 15,547,673 | ||||||||||||||||
NET INCREASE
(DECREASE) IN CASH AND CASH EQUIVALENTS
|
(6,245,168 | ) | 878,674 | — | — | (5,366,494 | ) | |||||||||||||||
CASH AND
CASH EQUIVALENTS
|
||||||||||||||||||||||
BEGINNING OF
THE PERIOD
|
32,711,636 | 738,157 | — | — | 33,449,793 | |||||||||||||||||
END OF THE
PERIOD
|
$ | 26,466,468 | $ | 1,616,831 | $ | — | $ | — | $ | 28,083,299 |
For the three months ended March 31, 2013
|
Parent
|
Guarantor
Sub sidiary |
Non-
Guarantor Sub sidiaries |
Eliminations
|
Consolidated
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS
FROM OPERATING ACTIVITIES
|
||||||||||||||||||||||
Net
income
|
$ | 67,134 | $ | 5,574,635 | $ | 5,833,894 | $ | (11,408,529 | ) | $ | 67,134 | |||||||||||
Adjustments to
reconcile net loss to cash:
|
||||||||||||||||||||||
(Equity) loss
of subsidiaries
|
(5,526,115 | ) | (5,882,414 | ) | — | 11,408,529 | — | |||||||||||||||
Life
settlements — change in fair value
|
— | — | (11,494,725 | ) | — | (11,494,725 | ) | |||||||||||||||
Amortization
of deferred financing and issuance costs
|
393,477 | 272,505 | 427,765 | — | 1,093,747 | |||||||||||||||||
Deferred
income taxes
|
563,874 | — | — | — | 563,874 | |||||||||||||||||
Preferred
stock issued for dividends
|
83,702 | — | — | — | 83,702 | |||||||||||||||||
(Increase)
decrease in operating assets:
|
||||||||||||||||||||||
Other
assets
|
(14,274,237 | ) | (10,700,326 | ) | 669,198 | 24,856,539 | 551,174 | |||||||||||||||
Increase in
operating liabilities:
|
||||||||||||||||||||||
Accounts
payable and other accrued expenses
|
844,042 | 131,527 | 315,187 | — | 1,290,756 | |||||||||||||||||
NET CASH
FLOWS USED IN OPERATING ACTIVITIES
|
(17,848,123 | ) | (10,604,073 | ) | (4,248,681 | ) | 24,856,539 | (7,844,338 | ) | |||||||||||||
CASH FLOWS
FROM INVESTING ACTIVITIES
|
||||||||||||||||||||||
Investment in
life settlements
|
— | — | (9,913,049 | ) | — | (9,913,049 | ) | |||||||||||||||
Proceeds from
settlement of life settlements
|
— | — | 1,490,000 | — | 1,490,000 | |||||||||||||||||
NET CASH
FLOWS USED IN INVESTING ACTIVITIES
|
— | — | (8,423,049 | ) | — | (8,423,049 | ) | |||||||||||||||
CASH FLOWS
FROM FINANCING ACTIVITIES
|
||||||||||||||||||||||
Net proceeds
from revolving credit facility
|
— | — | 8,000,000 | — | 8,000,000 | |||||||||||||||||
Payments for
redemption of Series I Secured notes payable
|
— | (1,507,824 | ) | — | — | (1,507,824 | ) | |||||||||||||||
Proceeds from
issuance of debentures
|
23,850,794 | — | — | — | 23,850,794 | |||||||||||||||||
Payments for
issuance costs and redemption of Renewable Secured Debentures
|
(2,303,268 | ) | — | — | — | (2,303,268 | ) | |||||||||||||||
Proceeds
(payments) from restricted cash
|
— | 1,469,676 | (6,000,784 | ) | — | (4,531,108 | ) | |||||||||||||||
Payments for
redemption of preferred stock
|
(186,669 | ) | (186,669 | ) | ||||||||||||||||||
NET CASH FLOWS
PROVIDED BY FINANCING ACTIVITIES
|
21,360,857 | 14,145,877 | 12,671,730 | (24,856,539 | ) | 23,321,925 | ||||||||||||||||
NET INCREASE IN
CASH AND CASH EQUIVALENTS
|
3,512,734 | 3,541,804 | — | — | 7,054,538 | |||||||||||||||||
CASH AND
CASH EQUIVALENTS
|
||||||||||||||||||||||
BEGINNING OF
THE PERIOD
|
25,035,579 | 2,461,465 | — | — | 27,497,044 | |||||||||||||||||
END OF THE
PERIOD
|
$ | 28,548,313 | $ | 6,003,269 | $ | — | $ | — | $ | 34,551,582 |
March 31,
2014 |
December 31,
2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Life insurance company
|
% | % | ||||||||
Company A
|
15.98 | 16.58 | ||||||||
Company B
|
11.13 | 11.34 |
March 31,
2014 |
December 31,
2013 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
State of residence
|
% | % | ||||||||
California
|
27.97 | 28.14 | ||||||||
Florida
|
15.38 | 15.59 | ||||||||
New York
|
10.84 | 10.65 |
Securities and
Exchange Commission registration fee
|
$ | 1,932 | ||||
FINRA filing
fee
|
$ | 70,000 | ||||
NASDAQ listing
fee
|
$ | 80,000 | ||||
Accounting
fees and expenses
|
$ | 200,000 | ||||
Legal fees and
expenses
|
$ | 350,000 | ||||
Transfer agent
and registrar fees
|
$ | 30,000 | ||||
Printing
expenses
|
$ | 80,000 | ||||
Miscellaneous
|
$ | 188,068 | ||||
Total
|
$ | 1,000,000 |
(a)
|
Exhibits . The exhibits listed below are filed as a part of this registration statement. |
Exhibit
Number |
Description
|
|||||
---|---|---|---|---|---|---|
1.1 |
Form
of Underwriting Agreement (to be filed by amendment)
|
|||||
3.1 |
Certificate of Incorporation (2)
|
|||||
3.2 |
Certificate of Amendment of Certificate of Incorporation (3)
|
|||||
3.3 |
Certificate of Designations for Series A Convertible Preferred Stock (3)
|
|||||
3.4 |
Bylaws (2)
|
|||||
4.1 |
Indenture with Bank of Utah, dated October 19, 2011 (relating to Renewable Secured Debentures) (4)
|
|||||
4.2 |
Form
of Renewable Secured Debenture (3)
|
|||||
4.3 |
Form
of Subscription Agreement (relating to Renewable Secured Debentures) (revised November 2013) (11)
|
|||||
4.4 |
Pledge and Security Agreement by and among GWG Holdings, Inc., GWG Life Settlements, LLC, Jon R. Sabes, Steven F. Sabes, and Bank of Utah,
dated October 19, 2011 (relating to Renewable Secured Debentures) (4)
|
|||||
4.5 |
Intercreditor Agreement by and among Bank of Utah, and Lord Securities Corporation, dated October 19, 2011 (relating to Renewable Secured
Debentures) (4)
|
|||||
4.6 |
Amendment No. 1 to Indenture with Bank of Utah, dated December 15, 2011 (relating to Renewable Secured Debentures)
(7)
|
|||||
4.7 |
Amendment No. 1 to Pledge and Security Agreement, dated December 15, 2011 (relating to Renewable Secured Debentures)
(7)
|
|||||
5.1 |
Opinion of Maslon Edelman Borman & Brand, LLP (to be filed by amendment)
|
|||||
10.1 |
Amended and Restated Credit and Security Agreement with DZ Bank AG Deutsche Zentral-Genossenschaftsbank (as agent), and Autobahn Funding
Company LLC (as lender), dated effective January 25, 2013 (8)*
|
|||||
10.2 |
Performance Guaranty of GWG Holdings, LLC dated July 15, 2008, delivered in favor of DZ Bank AG Deutsche Zentral-Genossenschaftsbank (as
agent), and Autobahn Funding Company LLC (as lender) (3)
|
|||||
10.3 |
General Reaffirmation and Modification Agreement dated effective January 29, 2013 delivered in favor of DZ Bank AG Deutsche
Zentral-Genossenschaftsbank (as agent), and Autobahn Funding Company LLC (as lender) (11)**
|
Exhibit
Number |
Description
|
||||||
---|---|---|---|---|---|---|---|
10.4 |
Third
Amended and Restated Note Issuance and Security Agreement dated November 1, 2011, with Lord Securities Corporation (as trustee), GWG LifeNotes Trust
(as secured party), and noteholders (11)
|
||||||
10.5 |
Pledge Agreement dated November 15, 2010, among Jon R. Sabes, Steven F. Sabes, Opportunity Finance, LLC, SFS Trust 1976, SFS Trust 1992
Esther, SFS Trust 1982, Mokeson, LLC (collectively as pledgors), and Lord Securities Corporation (as trustee and pledgee) (3)
|
||||||
10.6 |
Fourth Amended and Restated Managing Broker-Dealer Agreement with Arque Capital dated effective April 5, 2013 (11)***
|
||||||
10.7 |
Amended and Restated Investment Agreement with Insurance Strategies Fund, LLC, dated as of September 3, 2009 (3)
|
||||||
10.8 |
Addendum No. 1 to Sub-Sublease Agreement effective as of July 14, 2008 by Opportunity Finance, LLC and GWG Life, LLC (6)
|
||||||
10.9 |
Employment Agreement with Jon R. Sabes, dated June 14, 2011 (5)
|
||||||
10.10 |
Employment Agreement with Steven F. Sabes, dated June 14, 2011 (5)
|
||||||
10.11 |
Employment Agreement with Paul A. Siegert, dated June 14, 2011 (5)
|
||||||
10.12 |
Purchase and Sale Agreement with Athena Securities Group Ltd. and Athena Structured Funds PLC, dated July 11, 2011 (3)
|
||||||
10.13 |
Shareholders’ Agreement with respect to Athena Structured Funds PLC, dated July 11, 2011 (3)(12)
|
||||||
10.14 |
Amendment to Third Amended and Restated Note Issuance and Security Agreement, dated as of November 18, 2013, with Lord Securities Corporation
(as trustee for the GWG LifeNotes Trust) (11)
|
||||||
10.15 |
Purchase and Sale Agreement among GWG Holdings, Inc., Athena Securities Group Limited and GWG Securities International Public Limited Company,
dated June 28, 2013 (10)
|
||||||
10.16 |
2013
Stock Incentive Plan dated March 27, 2013 (9)
|
||||||
10.17 |
Form
of Stock Option Agreement used under 2013 Stock Incentive Plan (revised June 2014) ( filed herewith)****
|
||||||
10.18 |
Addendum to Third Amended and Restated Managing Broker-Dealer Agreement with Arque Capital dated effective February 28, 2013
(13)
|
||||||
10.19 |
Employment Agreement with William Acheson, dated May 30, 2014 (filed herewith)
|
||||||
10.20 |
Amendent No. 1 to Amended and Restated Credit and Security Agreement with DZ Bank AG Deutsche Zentral-Genossenschaftsbank and Autobahn
Funding Company LLC, dated May 29, 2014 (filed herewith)
|
||||||
21 |
List
of Subsidiaries (9)
|
||||||
23.1 |
Consent of Mayer Hoffman McCann P.C. (filed herewith)
|
||||||
23.2 |
Consent of Baker Tilly Virchow Krause, LLP (filed herewith)
|
||||||
23.3 |
Consent of Maslon Edelman Borman & Brand, LLP (to be contained within Exhibit 5.1 above)
|
||||||
99.1 |
Letter from Model Actuarial Pricing Systems, dated April 30, 2014 (1)
|
||||||
99.2 |
Copy
of First Confidential Draft Registration Statement on Form S-1 Submitted February 12, 2014 (14)
|
||||||
99.3 |
Copy
of Second Confidential Draft Registration Statement on Form S-1 Submitted March 28, 2014 (14)
|
||||||
|
|||||||
(1) |
Incorporated by reference to Quarterly Report on Form 10-Q for the period ended March 31, 2014, filed on May 6, 2014.
|
||||||
(2) |
Incorporated by reference to Form S-1 Registration Statement filed on June 14, 2011 (File No. 333-174887).
|
Exhibit
Number |
Description
|
|||||
---|---|---|---|---|---|---|
(3) |
Incorporated by reference to Form S-1/A Registration Statement filed on August 23, 2011 (File No. 333-174887).
|
|||||
(4) |
Incorporated by reference to Form S-1/A Registration Statement filed on October 20, 2011 (File No. 333-174887).
|
|||||
(5) |
Incorporated by reference to Form S-1/A Registration Statement filed on September 20, 2011 (File No. 333-174887).
|
|||||
(6) |
Incorporated by reference to Form S-1/A Registration Statement filed on July 26, 2011 (File No. 333-174887).
|
|||||
(7) |
Incorporated by reference to Post-Effective Amendment No. 1 to Form S-1/A filed on April 30, 2012 (File No. 333-174887).
|
|||||
(8) |
Incorporated by reference to Current Report on Form 8-K filed on February 1, 2013.
|
|||||
(9) |
Incorporated by reference to Annual Report on Form 10-K for the period ended December 31, 2013, filed on March 20, 2014.
|
|||||
(10) |
Incorporated by reference to Current Report on Form 8-K filed on July 8, 2013.
|
|||||
(11) |
Incorporated by reference to Post-Effective Amendment No. 8 to Form S-1/A filed on November 12, 2013 (File No. 333-174887).
|
|||||
(12) |
Agreement was terminated effective June 28, 2013.
|
|||||
(13) |
Incorporated by reference to Post-Effective Amendment No. 6 to Form S-1/A filed on April 4, 2013 (File No.
333-174887).
|
|||||
(14) |
Incorporated by reference to Form S-1 Registration Statement filed on April 25, 2014 (File No. 333-195505).
|
|||||
* |
The
registrant has earlier filed the original Credit and Security Agreement dated July 15, 2008, Consent and Amendment No. 1 to the Credit and Security
Agreement dated December 14, 2010, and Consent and Amendment No. 2 to the Credit and Security Agreement dated June 10, 2011. These documents were filed
as Exhibits 10.1, 10.2 and 10.3, respectively, to the Form S-1/A Registration Statement filed on August 23, 2011.
|
|||||
** |
The
registrant has earlier filed a Reaffirmation of Guaranty dated as of June 10, 2011, which was filed as Exhibit 10.7 to the Form S-1/A Registration
Statement filed on August 23, 2011.
|
|||||
*** |
The
registrant has earlier filed a Managing Broker-Dealer Agreement dated August 14, 2011, an amended Managing Broker-Dealer Agreement dated October 19,
2011, an Amended and Restated Managing Broker-Dealer Agreement dated November 16, 2011, and a Second Amended and Restated Managing Broker-Dealer
Agreement dated effective as of November 16, 2011. These documents were filed as Exhibits 10.8 to the Form S-1/A Registration Statements filed on
August 23, October 20, November 28 and December 15, 2011, respectively.
|
|||||
**** |
The registrant has earlier filed a Form of Stock Option Agreement for use under the 2013 Stock Incentive Plan, which was filed as Exhibit
10.17 to the registrant’s Annual Report on Form 10-K filed on March 20, 2014.
|
|
GWG
Holdings, INC.
|
|||||||||
|
By:
|
/s/ Jon R. Sabes
|
||||||||
|
|
Chief
Executive Officer
|
Name
|
Title
|
|||||
---|---|---|---|---|---|---|
/s/ Jon R. Sabes
|
Director, Chief Executive Officer
|
|||||
Jon R.
Sabes
|
(Principal Executive Officer)
|
|||||
/s/ Paul A. Siegert *
|
Director, Executive Chairman
|
|||||
Paul A.
Siegert
|
||||||
/s/ William Acheson
|
Chief
Financial Officer
|
|||||
William
Acheson
|
(Principal Financial and Accounting Officer)
|
|||||
/s/ Steven F. Sabes *
|
Director, President and Secretary
|
|||||
Steven F.
Sabes
|
||||||
/s/ David H. Abramson *
|
Director
|
|||||
David H.
Abramson
|
||||||
/s/ Charles H. Maguire III *
|
Director
|
|||||
Charles H.
Maguire III
|
||||||
/s/ Jeffrey L. McGregor *
|
Director
|
|||||
Jeffrey L.
McGregor
|
* Signed pursuant to power of attorney held by Jon R. Sabes.
Exhibit
Number |
Description
|
|||||
---|---|---|---|---|---|---|
10.17 |
Form of Stock Option Agreement used under 2013 Stock Incentive Plan
|
|||||
10.19 |
Employment Agreement with William Acheson, dated May 30, 2014
|
|||||
10.20 |
Amendment No. 1 to Amended and Restated Credit and Security Agreement with DZ Bank AG Deutsche Zentral-Genossenschaftsbank and Autobahn
Funding Company LLC, dated May 29, 2014
|
|||||
23.1 |
Consent of Mayer Hoffman McCann P.C.
|
|||||
23.2 |
Consent of Baker Tilly Virchow Krause, LLP
|
Number of Shares To Be Vested
|
Vesting Date or Condition
|
|
The shares represented by this certificate have not been registered or qualified under federal or state securities laws. The shares may not be offered for sale, sold, pledged or otherwise disposed of unless so registered or qualified, unless an exemption exists or unless such disposition is not subject to the federal or state securities laws. In its discretion, the Company may require that the availability of any exemption or the inapplicability of such securities laws be established by an opinion of counsel, the form and substance of which opinion shall be reasonably satisfactory to the Company.
|
If to the Company : | GWG Holdings, Inc. | |||
Attention: Chief Executive Officer and Chief Financial Officer | ||||
220 South Sixth Street, Suite 1200 | ||||
Minneapolis, MN 55402 | ||||
Facsimile: (612) 746-0445 | ||||
If to Optionee : | ||||
|
o
|
by cash, uncertified or certified check or bank draft;
|
|
o
|
by delivery of shares of common stock; or
|
|
o
|
by instructing the Company to withhold from the shares issuable upon exercise of the Option shares of common stock in payment of $____________ of the exercise price (and/or any related withholding tax obligations, if permissible under applicable law).
|
(Signature) | ||||
|
||||
(Address) | ||||
(Address) | ||||
(Social Security or other Tax ID No.)
|
1.
|
Term.
The term of employment shall be one year and shall automatically renew for one year periods unless terminated prior to such renewal by the Board of Directors.
|
2.
|
Duties.
Employee duties shall be to generally lead and direct the financial activities of the business and to undertake duties or as otherwise directed by the Board of Directors or CEO. Hours of work shall be as necessary to fulfill assigned duties.
|
3.
|
Salary.
The Employer shall pay the Employee an annual salary of $200,000.00, payable periodically in accordance with the Employer’s normal compensation schedules. The Employee’s salary shall be reviewed by the Board of Directors from time-to-time as appropriate.
|
4.
|
Incentive
Compensation
. The Employer shall pay the Employee an annual incentive compensation bonus, in the form of cash and stock options of the Employer in addition to Salary based upon the performance of the Employee. The Employee’s incentive compensation shall be determined by the Board of Directors as appropriate.
|
5.
|
Deductions.
The Employer shall deduct from compensation payable to the Employee such amounts as is required by law to deduct, including but not limited to federal and state withholding taxes, social security taxes and state disability insurance, and any other amounts as may be required pursuant to the Employer's benefit programs of which the Employee is a participant.
|
6.
|
Expenses.
The Employer shall reimburse the Employee for all appropriate and reasonable business expenses incurred by the Employee in performing the Employee’s duties. Such expenses shall include all legal expenses of the Employee for any liability or alleged liability related to the Employer incurred during the scope of employment with the Employer.
|
7.
|
Paid
Time
Off.
The Employee will be eligible for four weeks Paid Time Off annually. Paid Time Off may be used for vacation, illness, personal days, or other
reasons. Please refer to the Company Handbook for a detailed explanation. The Employee shall also be entitled to paid holidays.
|
8.
|
Health
Benefits.
The Employer offers health insurance options to both the Employee and the Employee’s dependents under its comprehensive benefits Program.
|
9.
|
Flexible
Spending
Account
Benefits.
The Employee will be eligible for enrollment in the Company Flexible Spending Account (FSA) in accordance with terms of the FSA.
|
10.
|
Retirement
Benefits
and
Severance
Package.
The Employee will be eligible for enrollment in the Company 401K/Roth 401K. Currently, the Company retirement plans do not include any Employer Match or Discretionary Contributions.
|
11.
|
Severance Package.
If the Employee's employment is terminated by Employer without 'good cause' or if the Employee voluntarily resigns with 'good reason' then the employee will be entitled to (i) severance pay for a period of 12 months and (ii) reimbursement of health insurance premiums for his family if he elects continued coverage under COBRA. At the discretion of the Employer, severance pay (representing 12 months of compensation) may be paid in a lump sum within 7 days following the date of termination.
|
12.
|
Notices.
Any notice required or provided to be given under this Agreement shall be sufficient if in writing, sent by first class mail, to the Employee’s residence in the case of notice to the Employee or to its principal office in the case of the Employer.
|
13.
|
Consent
to
Background
Check
. The Employee acknowledges the Employer is engaged in the financial services business and therefore must check the background information on all Employees and contractors.
|
14.
|
Company
Policy.
The Employee acknowledges and agrees to adhere to by signing the Employee Confidentiality Agreement, Privacy Policy, and Acknowledgement of Receipt and Understanding of the Employee Handbook. The Employee acknowledges that the Employer reserves the right to modify or amend its policies at any time to protect confidential information of customers, the business, and vendors.
|
15.
|
Waiver
of
Breach.
The waiver by either party of a breach of any provision of this Agreement by the other party shall not operate or be construed as a waiver of any subsequent breach by such other party.
|
16.
|
Governing
Law.
This Agreement shall be interpreted and enforced in accordance with the laws of the State of Minnesota, and any action brought to enforce any provision of this Agreement or to commence any other action in connection therewith shall have its venue in Hennepin County of Minnesota.
|
17.
|
Anti-Solicitation.
Within eighteen (18) months after voluntary or involuntary employment termination, Employee shall not, within the Territories, directly or indirectly solicit, divert, service, accept or otherwise attempt to convert policies or other business provided by Employer from or with respect to (i) customers of Employer who were serviced by the Employee during employment or with whom Employee has had direct contact during employment; or (ii) customers of Employer’s Affiliates who were serviced by Employee during employment.
|
18.
|
Non-Compete.
Except as specifically authorized by the Employer in writing, the Employee warrants, covenants and represents to the Employer that during the term of this Agreement and for a period of one year after termination, they/he/she/it shall not use the Confidential Information, directly or indirectly, to the Employee’s own benefit or for the benefit of any affiliate, subsidiary, employer or related party of the Employee, or any other third party. Further, except as specifically authorized by the Employer in writing, the Employee specifically covenants, warrants and represents to the Company, its successors and/or assigns, the Employee will not for a period of one year after termination, directly or indirectly, compete with the Company, it successors or assigns in its business wherever located. This Section 17 shall survive termination of this Agreement.
|
19.
|
Blue
Pencil.
Should any court or tribunal declare the foregoing covenants to be unreasonable or void for any reason, the duration or scope of the covenant shall be modified to such duration and scope as to not be unreasonable, arbitrary or against public policy, and to be the maximum restrictions allowed under Minnesota Law. Employee acknowledges and agrees that the covenants in Sections 16 and 17 are reasonable and valid in geographical and temporal scope and in all other respects. If any court determines that any of the covenants in Sections 16 and 17, or any part thereof, is invalid or unenforceable, the reminder of the covenants shall not thereby be affected and shall be give full effect, without regard to the invalid portions. Further, if any court determines that any of the covenants of Sections 16 and 17, or any parts thereof, are unenforceable because of the duration or geographic scope of such provision, such court shall reduce the duration or scope of such provision, as the case may be, to the extent necessary to render it enforceable and, in its reduced form, such provision shall then be enforced.
|
20.
|
Partial
Invalidity.
If any provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions shall nevertheless continue in full force without being impaired or invalidated in any way.
|
21.
|
Modification.
This Agreement shall be modified only by writing, executed by both the Employee and the Employer.
|
Company |
Employee
|
|||
By: |
/s/ Jon Sabes
|
By: |
/s/ Bill Acheson
|
|
Title: |
Chief Executive Officer
|
Name: |
William Acheson
|
GWG DLP FUNDING II, LLC, as the Borrower | |||
By
|
/s/ Jon Sabes | ||
Name: | Jon Sabes, President | ||
Title: |
GWG LIFE SETTLEMENTS, LLC, as the Seller and the Master Servicer | |||
By
|
/s/ Jon Sabes | ||
Name: | Jon Sabes, Chief Executive Officer | ||
Title: |
GWG HOLDINGS, INC., as Performance Guarantor | |||
By
|
/s/ Jon Sabes | ||
Name: | Jon Sabes, Chief Executive Officer | ||
Title: |
DZ BANK AG DEUTSCHE
ZENTRAL-GENOSSENSCHAFTSBANK, as
Agent and as Committed Lender
|
|||
By
|
|||
Name: | |||
Title: |
By
|
|||
Name: | |||
Title: |
AUTOBAHN FUNDING COMPANY LLC, as
Conduit Lender
|
|||
By:
|
DZ BANK AG DEUTSCHE | ||
ZENTRAL-GENOSSENSCHAFTSBANK, its
Attorney-in-Fact
|
By
|
|||
Name: | |||
Title: |
By
|
|||
Name: | |||
Title: |